

Query Match 100.0%; Score 19; DB 2; Length 64;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 TTKL 4
Db 47 TTKL 50

RESULT 13
C46448
Hypothetical protein 65 (rpoF or cpeB 3' region) - *Synechococcus* sp. (fragment)
C;Species: *Synechococcus* sp.
C;Date: 10-Jun-1993 #sequence_revision 01-Dec-1995 #text_change 09-Jul-2004
C;Accession: C46448; S31065
R;Wilbanks, S.M.; Glazer, A.N., 1993
J. Biol. Chem. 268, 1226-1235, 1993
A;Title: Rod structure of a phycoerythrin II-containing phycobilisome. I. Organization a
chococcus sp. WH8020..
A;Reference number: A45045; MUID:93123238; PMID:8419325
A;Accession: C46448
A;Status: preliminary; not compared with conceptual translation
A;Molecule type: DNA
A;Residues: 1-65 <WIL>
A;Cross-references: UNIPROT:Q02191; UNIPARC:UPI000013C004; EMBL:M95288; NID:g154551; PID
A;Experimental source: strain WH8020
A;Note: sequence extracted from NCBI backbone (NCBIP:121986)
C;Superfamily: protein-tyrosine-phosphatase, low molecular weight

Query Match 100.0%; Score 19; DB 2; Length 65;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 TTKL 4
Db 2 TTKL 5

RESULT 14
TI7731
Hypothetical protein a240L - *Chlorella* virus PBCV-1
C;Species: *Chlorella* virus PBCV-1
C;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 09-Jul-2004
C;Accession: TI7731
R;Graves, M.V.; Van Etten, J.L.
submitted to the EMBL Data Library, May 1999
A;Reference number: Z1806
A;Accession: TI7731
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-65 <GRA>
A;Cross-references: UNIPROT:Q84560; UNIPARC:UPI00000F47E5; EMBL:U42580; NID:g4028896; PI
A;Experimental source: specific host *Chlorella* strain NC64A
C;Genetics:
A;Note: a240L

Query Match 100.0%; Score 19; DB 2; Length 65;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 TTKL 4
Db 44 TTKL 47

RESULT 15
AB1660
Hypothetical protein lin1819 [imported] - *Listeria innocua* (strain Clip11262)
C;Species: *Listeria innocua*
C;Date: 27-Nov-2001 #sequence_revision 27-Nov-2001 #text_change 09-Jul-2004
C;Accession: AB1660
R;Glaser, P.; Frangeul, L.; Buchrieser, C.; Amend, A.; Baquero, F.; Berche, P.; Bloecker

..; Dominguez-Bernal, G.; Duchaud, E.; Durand, L.; Dussurget, O.; Entian, K.D.; Fsihi, H.;
D.; Jones, L.M.; Karst, U.
Science 294, 849-852, 2001
A;Authors: Kreft, J.; Kuhn, M.; Kunst, F.; Kurapkat, G.; Madueno, E.; Maitournam, A.; Mat
ok, C.; Schlueter, T.; Simoes, N.; Tierrez, A.; Vazquez-Boland, J.A.; Voss, H.; Wehland,
A;Title: Comparative genomics of *Listeria* species.
A;Reference number: AB1077; MUID:21537279; PMID:11679669
A;Accession: AB1660
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-73 <GLA>
A;Cross-references: UNIPROT:Q92AV0; UNIPARC:UPI00000CC68E; GB:AL592022; PIDN:CAC97050.1;
A;Experimental source: strain Clip11262
C;Genetics:
A;Gene: lin1819

Query Match 100.0%; Score 19; DB 2; Length 73;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 TTKL 4
Db 19 TTKL 22

Search completed: September 20, 2006, 07:03:58
Job time : 22.2 secs

C:Species: Xylella fastidiosa
 C>Date: 18-Aug-2000 #sequence_revision 20-Aug-2000 #text_change 09-Jul-2004
 C:Accession: H82784
 R:Anonymous, The Xylella fastidiosa Consortium of the Organization for Nucleotide Sequencing 406, 151-157, 2000
 A>Title: The genome sequence of the plant pathogen Xylella fastidiosa.
 A:Reference number: A82515; MUID:20365717; PMID:10910347
 A>Note: for a complete list of authors see reference number A59328 below
 A:Accession: H82784
 A>Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-53 <SIM>
 A:Cross-references: UNIPROT:Q9PFQ3; UNIPARC:UPI00000C2482; GB:AE003849; NID:10910347
 A:Experimental source: strain 9a5c
 R:Simpson, A.J.G.; Reinach, F.C.; Arruda, P.; Abreu, F.A.; Acencio, M.; Alvarenga, R.; Briones, M.R.S.; Bueno, M.R.P.; Camargo, A.A.; Camargo, L.E.A.; Carraro, D.M.; Carrer, H. et al., 2000
 A:Authors: Ferreira, V.C.A.; Ferro, J.A.; Fraga, J.S.; Franca, S.C.; Franco, M.C.; Frohm J.D.; Junqueira, M.L.; Kemper, E.L.; Kitajima, J.P.; Krieger, J.E.; Kuramae, E.E.; Laigret, M.A.; Madeira, A.M.B.N.; Madeira, H.M.F.; Marino, C.L.; Marques, M.V.; Martins, E.A.; Authors: Martins, E.M.F.; Matsukuma, A.Y.; Menck, C.F.M.; Miracca, E.C.; Miyaki, C.Y.; F.G.; Nunes, L.R.; Oliveira, M.A.; de Oliveira, M.C.; de Oliveira, R.C.; Palmieri, D.A.; Rodrigues, V.; Rosa, A.J. de M.; de Rosa Jr., V.E.; de Sa, R.G.; Santelli, R.V.; Sawasak A:Authors: da Silva, A.C.R.; da Silva, F.R.; da Silva, A.M.; Silva Jr., W.A.; da Silveira M.; Tshako, M.H.; Vallada, H.; Van Sluys, M.A.; Verjovski-Almeida, S.; Vettore, A.L.; Z A:Reference number: A59328
 A:Contents: annotation
 C:Genetics:
 A:Gene: XF0604

Query Match 100.0%; Score 19; DB 2; Length 53;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTKL 4
 ||||
 Db 18 TTKL 21

RESULT 9
 D81053
 hypothetical protein NMB1706 [imported] - Neisseria meningitidis (strain MC58 serogroup C:Species: Neisseria meningitidis
 C>Date: 31-Mar-2000 #sequence_revision 31-Mar-2000 #text_change 09-Jul-2004
 C:Accession: D81053
 R:Tetzelin, H.; Saunders, N.J.; Heidelberg, J.; Jeffries, A.C.; Nelson, K.E.; Eisen, J.A. Hickey, E.K.; Haft, D.H.; Salzberg, S.L.; White, O.; Fleischmann, R.D.; Dougherty, B.A.; ri, H.; Qin, H.; Vamathevan, J.; Gill, J.; Scarlato, V.; Maignani, V.; Pizza, M. Science 287, 1809-1815, 2000
 A:Authors: Grandi, G.; Sun, L.; Smith, H.O.; Fraser, C.M.; Moxon, E.R.; Rappuoli, R.; Ver A:Title: Complete genome sequence of Neisseria meningitidis serogroup B strain MC58.
 A:Reference number: A81000; MUID:20175755; PMID:10710307
 A:Accession: D81053
 A>Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-56 <ET>
 A:Cross-references: UNIPROT:Q9JY74; UNIPARC:UPI00000C4792; GB:AE002520; GB:AE002098; NID A:Experimental source: serogroup B, strain MC58
 C:Genetics:
 A:Gene: NMB1706

Query Match 100.0%; Score 19; DB 2; Length 56;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTKL 4
 ||||
 Db 4 TTKL 7

RESULT 10
 T26375

hypothetical protein Y102E9.4 - Caenorhabditis elegans
 C:Species: Caenorhabditis elegans
 C>Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 09-Jul-2004
 C:Accession: T26375
 R:Fulton, L.
 A:Submitted to the EMBL Data Library, February 1996
 A:Description: The sequence of C. elegans cosmid Y102E9.
 A:Reference number: Z20206
 A:Accession: T26375
 A>Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 1-59 <FUL>
 A:Cross-references: UNIPROT:Q23235; UNIPARC:UPI0000082B04; EMBL:U49954; PIDN:AAA93429.1;
 C:Genetics:
 A:Gene: CESP:Y102E9.4

Query Match 100.0%; Score 19; DB 2; Length 59;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTKL 4
 ||||
 Db 47 TTKL 50

RESULT 11

B64957
 hypothetical protein b1933 - Escherichia coli (strain K-12)
 C:Species: Escherichia coli
 C>Date: 12-Sep-1997 #sequence_revision 17-Sep-1997 #text_change 01-Mar-2002
 C:Accession: B64957
 R:Blattner, F.R.; Plunkett III, G.; Bloch, C.A.; Perna, N.T.; Burland, V.; Riley, M.; Col .A.; Rose, D.J.; Mau, B.; Shao, Y. Science 277, 1453-1462, 1997
 A:Title: The complete genome sequence of Escherichia coli K-12.
 A:Reference number: A64720; MUID:97426617; PMID:9278503
 A:Accession: B64957
 A>Status: nucleic acid sequence not shown; translation not shown
 A:Molecule type: DNA
 A:Residues: 1-63 <BLAT>
 A:Cross-references: UNIPARC:UPI00001680EB; GB:AE000286; GB:U00096; NID:G1788241; PIDN:AA A:Experimental source: strain K-12, substrain MGL1655

Query Match 100.0%; Score 19; DB 2; Length 63;
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTKL 4
 ||||
 Db 4 TTKL 7

RESULT 12

T09849
 cytochrome-c oxidase (EC 1.9.3.1) chain II - Geophagus steindachneri mitochondrion (frag C:Species: mitochondrion Geophagus steindachneri
 C>Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 31-Dec-2004
 C:Accession: T09849
 R:Normark, B.B.; McCune, A.R.; Harrison, R.G. Mol. Biol. Evol. 8, 819-834, 1991
 A:Title: Phylogenetic relationships of neopterygian fishes, inferred from mitochondrial A:Reference number: Z16885; MUID:92130804; PMID:1663569
 A>Status: translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 1-64 <NOR>

A:Cross-references: UNIPARC:UPI000016D53B; EMBL:M64892; NID:G337003; PIDN:AAB01458.1; PII C:Genetics:
 A:Genome: mitochondrion
 A:Genetic code: SGC1
 C:Superfamily: cytochrome-c oxidase, subunit II, mitochondrial type; cytochrome-c oxidase C:Keywords: copper; electron transfer; heme; membrane-associated complex; mitochondrial i ein

G82465
 hypothetical protein VCA0377 [imported] - Vibrio cholerae (strain N16961 serogroup O1)
 C:Species: Vibrio cholerae
 C>Date: 18-Aug-2000 #sequence_revision 20-Aug-2000 #text_change 09-Jul-2004
 C:Accession: G82465
 R:Heidelberg, J.F.; Eisen, J.A.; Nelson, W.C.; Clayton, R.A.; Gwinn, M.L.; Dodson, R.J.;
 chardson, D.; Ermolaeva, M.D.; Vamathevan, J.; Bass, S.; Qin, H.; Dragoi, I.; Sellers, F.
 l, R.R.; Mekalanos, J.J.; Venter, J.C.; Fraser, C.M.
 Nature 406, 477-483, 2000
 A:Title: DNA Sequence of both chromosomes of the cholera pathogen Vibrio cholerae.
 A:Reference number: A82035; MUID:20406833; PMID:10952301
 A:Accession: G82465
 A>Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-41 <HEI>
 A:Cross-references: UNIPROT:Q9KMH6; UNIPARC:UPI00000C34F0; GB:AE004374; GB:AE003853; NID
 A:Experimental source: serogroup O1; strain N16961; biotype El Tor
 C:Genetics:
 A:Gene: VCA0377
 A:Map position: 2

Query Match 100.0%; Score 19; DB 2; Length 41;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTTL 4
 ||||
 Db 16 TTTL 19

RESULT 4
 B60195
 transforming protein (Mcf2) long form - mouse (fragment)
 C:Species: Mus musculus (house mouse)
 C>Date: 03-Mar-1993 #sequence_revision 03-Mar-1993 #text_change 09-Jul-2004
 C:Accession: B60195
 R:Galland, F.; Pirisi, V.; deLapeyriere, O.; Birnbaum, D.
 Oncogene 6, 833-839, 1991
 A:Title: Restriction and complexity of Mcf2 proto-oncogene expression.
 A:Reference number: A60195; MUID:91270902; PMID:2052360
 A:Accession: B60195
 A>Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-42 <GAL>
 A:Cross-references: UNIPROT:Q9N972; UNIPARC:UPI00001764A8
 C:Superfamily: dbl transforming protein; CDC24 homology; plectstrin repeat homology

Query Match 100.0%; Score 19; DB 2; Length 42;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTTL 4
 ||||
 Db 12 TTTL 15

RESULT 5
 B85549
 hypothetical protein Z0655 [imported] - Escherichia coli (strain O157:H7, substrain EDL5
 C:Species: Escherichia coli
 C>Date: 16-Feb-2001 #sequence_revision 16-Feb-2001 #text_change 09-Jul-2004
 C:Accession: B85549
 R:Perna, N.T.; Plunkett III, G.; Burland, V.; Mau, B.; Glasner, J.D.; Rose, D.J.; Mayhew
 iller, L.; Grobeck, E.J.; Davis, N.W.; Lim, A.; Dimalanta, E.; Potamousis, K.; Apodaca,
 Nature 409, 523-533, 2001
 A:Title: Genome sequence of enterohemorrhagic Escherichia coli O157:H7.
 A:Reference number: A85480; MUID:21074935; PMID:11206551
 A:Accession: B85549
 A>Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-50 <STO>
 A:Cross-references: UNIPROT:Q8X4H0; UNIPARC:UPI00000D0DE0; GB:AE005174; NID:g12513393; F
 A:Experimental source: strain O157:H7, substrain EDL5933

C:Genetics:
 A:Gene: Z0655

Query Match 100.0%; Score 19; DB 2; Length 50;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTTL 4
 ||||
 Db 20 TTTL 23

RESULT 6
 F90548
 hypothetical protein MYPU 2940 [imported] - Mycoplasma pulmonis (strain UAB CTIP)
 C:Species: Mycoplasma pulmonis
 C>Date: 24-May-2001 #sequence_revision 24-May-2001 #text_change 09-Jul-2004
 C:Accession: F90548
 R:Chambaud, I.; Heilig, R.; Ferris, S.; Barbe, V.; Samson, D.; Galisson, F.; Moszer, I.;
 Nucleic Acids Res. 29, 2145-2153, 2001
 A:Title: The complete genome sequence of the murine respiratory pathogen Mycoplasma pulm
 A:Reference number: A99512; MUID:21267165; PMID:11353084
 A:Accession: F90548
 A>Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-51 <KUR>
 A:Cross-references: UNIPROT:Q98QR7; UNIPARC:UPI00000C8053; GB:AL445566; PID:g14089708; P
 A:Experimental source: strain UAB CTIP
 C:Genetics:
 A:Gene: MYPU 2940
 A:Genetic code: SGC3

Query Match 100.0%; Score 19; DB 2; Length 51;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTTL 4
 ||||
 Db 7 TTTL 10

RESULT 7
 E97132
 hypothetical protein CAC1884 [imported] - Clostridium acetobutylicum
 C:Species: Clostridium acetobutylicum
 C>Date: 14-Sep-2001 #sequence_revision 14-Sep-2001 #text_change 09-Jul-2004
 C:Accession: E97132
 R:Nolling, J.; Breton, G.; Omelchenko, M.V.; Markarova, K.S.; Zeng, Q.; Gibson, R.; Lee,
 ; Daly, M.J.; Bennett, G.N.; Koonin, E.V.; Smith, D.R.
 J. Bacteriol. 183, 4823-4838, 2001
 A:Title: Genome Sequence and Comparative Analysis of the Solvent-Producing Bacterium Clo
 A:Reference number: A96900; MUID:21359325; PMID:21359325
 A:Accession: E97132
 A>Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-51 <KUR>
 A:Cross-references: UNIPROT:Q97HX2; UNIPARC:UPI00000CA33C; GB:AE001437; PIDN:AAK79848.1;
 A:Experimental source: Clostridium acetobutylicum ATCC824
 C:Genetics:
 A:Gene: CAC1884

Query Match 100.0%; Score 19; DB 2; Length 51;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTTL 4
 ||||
 Db 6 TTTL 9

RESULT 8
 H82784
 hypothetical protein XF0604 [imported] - Xylella fastidiosa (strain 9a5c)

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: September 20, 2006, 06:56:38 ; Search time 19.2 Seconds
(without alignments)
20.045 Million cell updates/sec

Title: US-10-619-256-4
Perfect score: 19
Sequence: 1 TTKL 4

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues
Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 80:*
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	19	100.0	31	2	I61698	myosin - human (fr
2	19	100.0	33	2	S63523	formylmethanofuran
3	19	100.0	41	2	G82465	hypothetical prote
4	19	100.0	42	2	B60195	transforming prote
5	19	100.0	50	2	E85549	hypothetical prote
6	19	100.0	51	2	F90548	hypothetical prote
7	19	100.0	51	2	E97132	hypothetical prote
8	19	100.0	53	2	H82784	hypothetical prote
9	19	100.0	56	2	D81053	hypothetical prote
10	19	100.0	59	2	T26375	hypothetical prote
11	19	100.0	63	2	B64957	hypothetical prote
12	19	100.0	64	2	T09849	cytochrome-c oxida
13	19	100.0	65	2	C46448	hypothetical prote
14	19	100.0	65	2	T17731	hypothetical prote
15	19	100.0	73	2	A81660	hypothetical prote
16	19	100.0	73	2	AC1288	hypothetical prote
17	19	100.0	74	2	C96547	hypothetical prote
18	19	100.0	75	1	Q0BE36	BBLF1 protein - hu
19	19	100.0	76	2	T51499	hypothetical prote
20	19	100.0	79	2	D90992	hypothetical prote
21	19	100.0	79	2	F85837	hypothetical prote
22	19	100.0	82	2	AB2292	hypothetical prote
23	19	100.0	83	2	H84989	30S ribosomal prot
24	19	100.0	84	1	R3EC17	ribosomal protein
25	19	100.0	84	2	JC2275	ribosomal protein
26	19	100.0	84	2	H91150	30S ribosomal subu
27	19	100.0	84	2	D85996	30S ribosomal subu
28	19	100.0	84	2	AC0027	30S ribosomal prot
29	19	100.0	84	2	C64003	probable sodium-tr

30	19	100.0	85	1	E64093	ribosomal protein
31	19	100.0	87	2	A90095	40S ribosomal prot
32	19	100.0	89	2	T17491	hypothetical prote
33	19	100.0	92	2	AE3377	transposase BME111
34	19	100.0	92	2	AF3383	transposase BME110
35	19	100.0	92	2	AF3599	transposase BME110
36	19	100.0	92	2	AF3427	transposase BME114
37	19	100.0	94	2	H83655	hypothetical prote
38	19	100.0	99	2	AD1454	hypothetical prote
39	19	100.0	101	2	S73700	probable lipoprote
40	19	100.0	102	2	PN0597	DNA-directed DNA p
41	19	100.0	103	2	F81509	hypothetical prote
42	19	100.0	103	2	A97458	hypothetical prote
43	19	100.0	104	2	AD0289	probable lipoprote
44	19	100.0	107	2	AI2489	hypothetical prote
45	19	100.0	109	2	E89873	cysteine proteinase

ALIGNMENTS

RESULT 1

I61698
myosin - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 31-May-1996 #sequence_revision 31-May-1996 #text_change 09-Jul-2004
C;Accession: I61698
R;Bement, W.M.; Hasson, T.; Wirth, J.A.; Cheney, R.E.; Mooseker, M.S.
Proc. Natl. Acad. Sci. U.S.A. 91, 6549-6553, 1994
A;Title: Identification and overlapping expression of multiple unconventional myosin gene
A;Reference number: A55758; MUID:94294418; PMID:8022818
A;Accession: I61698
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-31 <RES>
A;Cross-references: UNIPROT:Q14786; UNIPARC:UPI00000713B8; GB:L29147; NID:9457255; PIDN:7

Query Match 100.0%; Score 19; DB 2; Length 31;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTKL 4
Db 2 TTKL 5

RESULT 2

S63523
formylmethanofuran dehydrogenase (EC 1.2.99.5) (molybdenum) chain B - Methanobacterium th
C;Species: Methanobacterium thermoautotrophicum
C;Date: 28-Oct-1996 #sequence_revision 16-Apr-1999 #text_change 16-Apr-1999
C;Accession: S63523
R;Hochheimer, A.; Schmitz, R.A.; Thauer, R.K.; Hedderich, R.
Eur. J. Biochem. 234, 910-920, 1995
A;Title: The tungsten formylmethanofuran dehydrogenase from Methanobacterium thermoautot
A;Reference number: S63519; MUID:96163477; PMID:8575452
A;Accession: S63523
A;Molecule type: protein
A;Residues: 1-16,17-26;27-33 <HOC>
A;Cross-references: UNIPARC:UPI000017AE80; UNIPARC:UPI000017AE81; UNIPARC:UPI000017AE82
A;Note: 29-Leu was also found
C;Keywords: iron-sulfur protein; metalloprotein; molybdenum; molybdopterin; oxidoreductase

Query Match 100.0%; Score 19; DB 2; Length 33;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTKL 4
Db 14 TTKL 17

RESULT 3

=> fil reg; d stat que 12; fil capl; d que nos 120
 FILE 'REGISTRY' ENTERED AT 15:03:57 ON 21 SEP 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 20 SEP 2006 HIGHEST RN 908067-83-4
 DICTIONARY FILE UPDATES: 20 SEP 2006 HIGHEST RN 908067-83-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer
 be available. Please contact CAS Customer Care
 (<http://www.cas.org/supp.html>) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

L2 2633 SEA FILE=REGISTRY ABB=ON T[AG]T[ATV]T[IV]/SQSP

Seq IDS

FILE 'CAPLUS' ENTERED AT 15:03:57 ON 21 SEP 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
 held by the publishers listed in the PUBLISHER (PB) field (available
 for records published or updated in Chemical Abstracts after December
 26, 1996), unless otherwise indicated in the original publications.
 The CA Lexicon is the copyrighted intellectual property of the
 American Chemical Society and is provided to assist you in searching
 databases on STN. Any dissemination, distribution, copying, or storing
 of this information, without the prior written consent of CAS, is
 strictly prohibited.

FILE COVERS 1907 - 21 Sep 2006 VOL 145 ISS 13
 FILE LAST UPDATED: 20 Sep 2006 (20060920/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
 They are available for your review at:

<http://www.cas.org/infopolicy.html>
 'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L2 2633 SEA FILE=REGISTRY ABB=ON T[AG]T[ATV]T[IV]/SQSP
 L3 1165 SEA FILE=CAPLUS ABB=ON L2
 L4 122 SEA FILE=CAPLUS ABB=ON (ADHES?(2A)ORGANELLE#)/BI
 L5 46234 SEA FILE=CAPLUS ABB=ON ANTIMICROB?/OBI
 L6 69896 SEA FILE=CAPLUS ABB=ON ANTIBACTERI?/OBI
 L7 1768 SEA FILE=CAPLUS ABB=ON PATHOGENIC BACTERIA/CT
 L8 13492 SEA FILE=CAPLUS ABB=ON INFECTION/CT(L)BACTERI?/OBI
 L15 14 SEA FILE=CAPLUS ABB=ON L3 AND (L4 OR L5 OR L7)
 L16 18 SEA FILE=CAPLUS ABB=ON L3 AND L6 AND L8
 L17 91355 SEA FILE=CAPLUS ABB=ON SCREENING/OBI
 L18 212501 SEA FILE=CAPLUS ABB=ON DRUG DELIVERY SYSTEMS+OLD/CT
 L19 22 SEA FILE=CAPLUS ABB=ON L3 AND (L6 OR L8) AND (L17 OR L18)
 L20 43 SEA FILE=CAPLUS ABB=ON (L19 OR L15 OR L16)

=> d ibib ed abs hitrn l20 1-43

L20 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:333587 CAPLUS

DOCUMENT NUMBER: 144:368356

TITLE: Immunogenic composition comprising staphylococcal poly-N-acetylglucosamine (PNAG)/PIA, capsular polysaccharides, and combination of antigens

INVENTOR(S): Castado, Cindy; Lecrenier, Nicolas Pierre Fernand; Neyt, Cecile Anne; Poolman, Jan

PATENT ASSIGNEE(S): GlaxoSmithKline Biologicals S.A., Belg.

SOURCE: PCT Int. Appl., 127 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006032500	A2	20060330	WO 2005-EP10260	20050920
WO 2006032500	A3	20060622		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:

GB 2004-21078	A	20040922
GB 2004-21079	A	20040922
GB 2004-21081	A	20040922
GB 2004-21082	A	20040922
GB 2005-3143	A	20050215

ED Entered STN: 12 Apr 2006

AB The present application relates to immunogenic compns. comprising staphylococcal poly-N-acetylglucosamine (PNAG)/PIA (polysaccharide intercellular adhesin) and Type 5 and/or 8 capsular polysaccharide or oligosaccharide from Staphylococcus aureus. PNAG (PIA) is highly

conserved among Gram pos. bacteria and provides protection against a broad range of bacteria whereas Type 5 and 8 polysaccharides are potent immunogens that elicit an immune response against most strains of *S. aureus* which is the most common cause of nosocomial infection. Vaccines, methods of treatment using and processes to make an immunogenic composition comprising PNAG and Type 5 and/or 8 capsular polysaccharides are also described. In other embodiments immunogenic compns. also comprise different combinations of staphylococcal antigens.

IT 881860-68-0, Protein EbhA (*Staphylococcus aureus*)

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; immunogenic composition comprising staphylococcal poly-N-acetylglucosamine (PNAG)/PIA and capsular polysaccharides, and combination of antigens)

L20 ANSWER 2 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:333508 CAPLUS

DOCUMENT NUMBER: 144:348884

TITLE: Effective immunogenic compositions comprising combinations of staphylococcal antigens and capsular polysaccharides

INVENTOR(S): Castado, Cindy; Fischer, Gerald Walter; Foster, Simon James; Kokai-Kun, John Fitzgerald; Lecrenier, Nicolas Pierre Fernand; Lees, Andrew; Mond, James Jacob; Neyt, Cecile Anne; Poolman, Jan

PATENT ASSIGNEE(S): GlaxoSmithKline Biologicals S.A., Belg.; The University of Sheffield; Biosynexus Incorporated

SOURCE: PCT Int. Appl., 136 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006032475	A2	20060330	WO 2005-EP10199	20050920
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:

GB 2004-21078	A	20040922
GB 2004-21079	A	20040922
GB 2004-21081	A	20040922
GB 2004-21082	A	20040922
GB 2005-3143	A	20050215

ED Entered STN: 12 Apr 2006

AB The present application relates to immunogenic compns. and vaccines, their manufacture and the use for the prevention or treatment of staphylococcal disease. More particularly, the invention provides immunogenic compns. or vaccines comprising lipoteichoic acid from Gram-pos. bacterium and *Staphylococcus aureus* capsular polysaccharides type 5 and/or 8. It also

provides vaccine compns. comprising combinations of staphylococcal antigens which allow a particularly effective immune response to be generated. Examples of such combinations include a iron-regulated protein HarA in combination with further staphylococcal antigens. It was shown that HarA is a particularly effective antigen to be incorporated into a mixture of staphylococcal protein antigens. Provided are protein and gene sequences from *S. aureus* and *S. epidermidis* for HarA and other antigens, including extracellular component binding proteins, toxins, transport proteins, regulators of virulence, and structural proteins. Methods for the treatment or prevention of staphylococcal infections using such vaccines are also provided.

IT 881704-53-6, Protein EbhA (*Staphylococcus aureus*)
 RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (amino acid sequence; effective immunogenic compns. comprising combinations of staphylococcal antigens and capsular polysaccharides)

L20 ANSWER 3 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:164886 CAPLUS

DOCUMENT NUMBER: 144:249254

TITLE: Cloning, sequence and characterization of human HectH9 protein involved in regulation of cell proliferation and death, and use of HectH9 inhibitors as anticancer agents

INVENTOR(S): Helin, Kristian; Marinoni, Federica; Grassilli, Emanuela

PATENT ASSIGNEE(S): Cancer Research Technology Limited, UK

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018654	A1	20060223	WO 2005-GB3247	20050819
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:

GB 2004-18630 A 20040820

US 2004-602873P P 20040820

US 2005-675886P P 20050429

ED Entered STN: 23 Feb 2006

AB Materials and methods for producing proteins involved in cell proliferation and apoptosis, particularly proliferation and apoptosis of tumor cells, are provided. Assays for identifying inhibitors of the proteins and methods for producing such inhibitors are also provided, as are methods of treatment using the inhibitors. More specifically, the invention provides HectH9 polypeptides and nucleic acids, agonists and inhibitors thereof, and their use in assays and methods of treatment. The

cdna sequence and the encoded protein sequence of human HectH9 are disclosed. It was shown that: (i) HectH9 is overexpressed in human tumors, (ii) HectH9 downregulation leads to growth arrest and morphol. changes in HeLa cells, (iii) HectH9 depletion impairs the growth of cancer cells but not primary fibroblasts. Inhibitors of HectH9 expression or activity can be used as anticancer agents.

IT 877096-63-4, Protein HectH9 (human)

RL: ANT (Analyte); BSU (Biological study, unclassified); BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(amino acid sequence; cloning, sequence and characterization of human HectH9 protein involved in regulation of cell proliferation and death, and use of HectH9 inhibitors as anticancer agents)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 4 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1168966 CAPLUS

DOCUMENT NUMBER: 143:458494

TITLE: Pathogen-derived antigens, polynucleotides and antibodies for diagnosis, prevention and treatment of traveler's diarrhea

INVENTOR(S): Meinke, Andreas; Triska, Christine; Henics, Tamas;

Minh Bui, Duc; Nagy, Eszter; Prustomersky, Sonja

PATENT ASSIGNEE(S): InterCell AG, Austria

SOURCE: PCT Int. Appl., 428 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005103073	A2	20051103	WO 2005-EP51857	20050426
WO 2005103073	A3	20060302		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2004-450095 A 20040427

ED Entered STN: 03 Nov 2005

AB The present invention discloses isolated nucleic acid mols. encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from traveler's diarrhea-causing bacteria such as enteroaggregative Escherichia coli, enterotoxigenic E. coli, Shigella flexneri, Campylobacter jejuni, etc. The invention also provides methods for isolating such antigens and use of vaccines, antibodies, ribozymes, antisense nucleic acids and siRNAs for diagnosis and treatment of traveler's diarrhea bacterial infection.

IT 868799-15-9P 868801-62-1P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);

PRP (Properties); BIOL (Biological study); PREP (Preparation)
(amino acid sequence; Escherichia coli, Shigella flexneri and
Campylobacter jejuni-derived antigens, polynucleotides and antibodies
for diagnosis, prevention and treatment of traveler's diarrhea)

L20 ANSWER 5 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:158798 CAPLUS

DOCUMENT NUMBER: 142:259970

TITLE: Immunoglobulin chimeric binding constructs and their
immunotherapeutic applications

INVENTOR(S): Ledbetter, Jeffrey A.; Hayden-Ledbetter, Martha S.;
Thompson, Peter A.

PATENT ASSIGNEE(S): Trubion Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 590 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005017148	A1	20050224	WO 2003-US41600	20031224
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005136049	A1	20050623	US 2003-627556	20030726
CA 2533921	AA	20050224	CA 2003-2533921	20031224
AU 2003300092	A1	20050307	AU 2003-300092	20031224
EP 1654358	A1	20060510	EP 2003-800349	20031224
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
NO 2006000764	A	20060420	NO 2006-764	20060217
PRIORITY APPLN. INFO.:			US 2003-627556	A 20030726
			US 2001-367358P	P 20010117
			US 2002-53530	A2 20020117
			WO 2003-US41600	W 20031224

ED Entered STN: 24 Feb 2005

AB The invention relates to novel binding domain-Ig fusion proteins that feature (1) a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, (2) a wild-type IgG, IgA or IgE hinge-acting region, or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and (3) Ig CH2 and CH3 domains. Parent monoclonal antibody Fv single-chain binding moieties include murine 2H7 (anti-human CD20), 40.2.220 (anti-human CD40), 2E12 (anti-human CD28), 10A8 (anti-human CD152/CTLA-4), G19-4 (anti-human CD3), L6 (anti-carcinoma), FC2-2 (anti-CD16), UCHL-1 (anti-CD45RO), HD37 (anti-CD19), G19-4 (anti-CD3), and 5B9 (anti-human 4-1BB/CD137), and rat 1D8 (anti-murine 4-1BB/CD137). The fusion proteins are capable of antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC) while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly

produced at high expression levels. Also provided are related compns. and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.

IT 845951-60-2P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; Ig chimeric binding constructs and their immunotherapeutic applications)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:98987 CAPLUS

DOCUMENT NUMBER: 142:171050

TITLE: Prediction of operons in Staphylococcus aureus and other microbial genomes with use of antisense nucleic acids for identification of proliferation-required operons

INVENTOR(S): Wang, Liangsu; Zamudio, Carlos

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 116 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005026189	A1	20050203	US 2004-857625	20040528
PRIORITY APPLN. INFO.:			US 2003-474768P	P 20030529

ED Entered STN: 04 Feb 2005

AB A method for predicting operons in prokaryotes, and particularly in the genome sequence Staphylococcus aureus strain Mu50, is provided. Operon prediction may be used to score the likelihood that adjacent gene pairs within a prokaryotic organism's genome are cotranscribed. Gene pairs are identified and segregated into discrete bins indicative of distinct operons on the basis of a calculated score using the consensus operon prediction model. Operon boundaries are identified by comparing the score associated with a selected gene pair with a threshold. The predicted operons, the genes contained therein, and the associated operon boundaries may be mapped back to the prokaryotic organism's genome to generate an annotated genomic map for the selected prokaryotic organism. Application to S. aureus demonstrated that >90% of the identified gene pairs were associated with operon prediction scores indicating a high confidence of either being in distinct operons or in the same operon; application of an empirically derived threshold for this organism predicted over 1397 operons (62% monocistronic and 38% polycistronic) from the protein-encoding genes in the S. aureus strain Mu50 genome, a high degree of accuracy when compared with exptl. determined values from the literature. Also described are vectors comprising operons predicted using the this method as well as methods of using antisense nucleic acids complementary to at least a portion of a predicted proliferation-required operon to inhibit cellular proliferation. Methods of using such antisense nucleic acids to sensitize cells for use in assays to identify compds. which possess the ability to inhibit cellular proliferation are also described.

IT 834940-01-1

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(amino acid sequence; prediction of operons in Staphylococcus aureus and other microbial genomes with use of antisense nucleic acids for identification of proliferation-required operons)

L20 ANSWER 7 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1059380 CAPLUS

DOCUMENT NUMBER: 142:36908

TITLE: Enterococcus faecalis-derived hyperimmune serum reactive antigens, vaccines, nucleic acids and antibodies for diagnosis and treatment of bacterial infection and for antagonist **screening**

INVENTOR(S): Meinke, Andreas; Nagy, Eszter; Hanner, Markus; Gelbmann, Dieter

PATENT ASSIGNEE(S): Intercell A.-G., Austria

SOURCE: PCT Int. Appl., 175 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004106367	A2	20041209	WO 2004-EP5664	20040526
WO 2004106367	A3	20050616		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004242842	A1	20041209	AU 2004-242842	20040526
CA 2525540	AA	20041209	CA 2004-2525540	20040526
EP 1629005	A2	20060301	EP 2004-739367	20040526
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
CN 1798761	A	20060705	CN 2004-80015159	20040526
PRIORITY APPLN. INFO.:			EP 2003-450137	A 20030530
			WO 2004-EP5664	W 20040526

ED Entered STN: 10 Dec 2004

AB The present invention discloses isolated nucleic acid mols. encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof. The antigens, nucleic acids encoding the antigens, vaccines, antibodies, antisense nucleic acids, siRNAs, anticalines, aptamers and spiegelmers are used for diagnosis and treatment of bacterial infection e.g. by Enterococcus, as well as for identifying antagonists.

IT 805334-30-9P 805337-13-7P

RL: ARU (Analytical role, unclassified); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; Enterococcus faecalis-derived hyperimmune serum

reactive antigens, vaccines, nucleic acids and antibodies for diagnosis and treatment of bacterial infection and for antagonist screening)

L20 ANSWER 8 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:996211 CAPLUS

DOCUMENT NUMBER: 141:423303

TITLE: Streptococcus agalactiae hyperimmune serum reactive antigens, nucleic acids and antibodies for vaccines, antagonist screening and diagnosis of bacterial infection

INVENTOR(S): Meinke, Andreas; Nagy, Eszter; Hanner, Markus; Horky, Markus; Kallenda, Sabine; Prustomersky, Sonja

PATENT ASSIGNEE(S): InterCell AG, Austria

SOURCE: PCT Int. Appl., 221 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099242	A2	20041118	WO 2004-EP4856	20040506
WO 2004099242	A3	20050616		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004235952	A1	20041118	AU 2004-235952	20040506
CA 2522986	AA	20041118	CA 2004-2522986	20040506
EP 1620460	A2	20060201	EP 2004-731346	20040506
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1784419	A	20060607	CN 2004-80012219	20040506
PRIORITY APPLN. INFO.:			EP 2003-450112	A 20030507
			EP 2003-450266	A 20031128
			WO 2004-EP4856	W 20040506

ED Entered STN: 19 Nov 2004

AB The present invention discloses isolated nucleic acid mols. encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, methods for isolating such antigens. The hyperimmune serum reactive antigens are useful as vaccines against bacterial infection, especially

infection by S. agalactiae; for raising antibodies (e.g. monoclonal antibodies, antibody fragments, chimeric and humanized antibodies); for screening antagonists; and for diagnosing bacterial infection. Also included in the invention are anticalines, aptamers and spiegelmers, and functional RNA comprising ribozymes, antisense nucleic acids and siRNA.

IT 795869-09-9P

RL: ARU (Analytical role, unclassified); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP

(Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; Streptococcus agalactiae hyperimmune serum reactive antigens, nucleic acids and antibodies for vaccines, antagonist **screening** and diagnosis of bacterial infection)

L20 ANSWER 9 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:902760 CAPLUS

DOCUMENT NUMBER: 141:343456

TITLE: Methods for identifying the target of a compound which inhibits cellular proliferation

INVENTOR(S): Carr, Grant J.; Xu, Howard H.; Foulkes, Gordon J.; Zamudio, Carlos; Haselbeck, Robert; Ohlsen, Kari L.; Zyskind, Judith W.; Wall, Daniel; Trawick, John D.; Yamamoto, Robert T.; Roemer, Terry; Jiang, Bo; Boone, Charles; Bussey, Howard

PATENT ASSIGNEE(S): Elitra Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 640 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002086097	A2	20021031	WO 2002-XB3987	20020208
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LK, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002086097	A2	20021031	WO 2002-US3987	20020208
WO 2002086097	A3	20030306		
WO 2002086097	C1	20041125		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2001-267636P P 20010209
WO 2002-US3987 A 20020208

ED Entered STN: 29 Oct 2004

AB The invention relates to cultures or collections of strains which overexpress or underexpress gene products required for the proliferation of an organism. The invention also includes methods for identifying the target on which a compound which inhibits the proliferation of an organism acts and methods for identifying the extent to which a strain is present in a culture or collection of strains. Thus, a culture is obtained comprising a plurality of strains wherein each strain overexpresses a

different gene product which is essential for proliferation. The culture is contacted with a sufficient concentration of an agent to inhibit the proliferation of strains which do not overexpress the gene product on which the agent acts, such that strains which overexpress the gene product on which the agent acts proliferate more rapidly than strains which do not overexpress said gene product on which the agent acts. The gene product which is overexpressed in a strain which proliferates more rapidly in the culture is then identified. Expression levels of gene transcripts are determined using hybridization and/or amplification methods standard to the art.

Genes required for cellular proliferation of microbial organisms are identified by antisense RNA technology. Nucleotide sequences are provided for nucleic acid fragments whose expression results in detrimental effects on proliferation of *Escherichia coli*, *Staphylococcus aureus*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, or *Enterococcus faecalis*. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 775480-57-4 775481-12-4 775483-52-8

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; target gene product identification for microbial cell proliferation-inhibiting compounds.)

L20 ANSWER 10 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:902756 CAPLUS
Correction of: 2002:832949

DOCUMENT NUMBER: 141:343454
Correction of: 137:346147

TITLE: Methods for identifying the target of a compound which inhibits cellular proliferation

INVENTOR(S): Carr, Grant J.; Xu, Howard H.; Foulkes, Gordon J.;
Zamudio, Carlos; Haselbeck, Robert; Ohlsen, Kari L.;
Zyskind, Judith W.; Wall, Daniel; Trawick, John D.;
Yamamoto, Robert T.; Roemer, Terry; Jiang, Bo; Boone, Charles; Bussey, Howard

PATENT ASSIGNEE(S): Elitra Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 640 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002086097	A2	20021031	WO 2002-US3987	20020208
WO 2002086097	A3	20030306		
WO 2002086097	C1	20041125		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2436216	AA	20021031	CA 2002-2436216	20020208

WO 2002086097 A2 20021031 WO 2002-XA3987 20020208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LK, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002086097 A2 20021031 WO 2002-XB3987 20020208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LK, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1360335 A2 20031112 EP 2002-728338 20020208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004528846 T2 20040924 JP 2002-583612 20020208
PRIORITY APPLN. INFO.: US 2001-267636P P 20010209
WO 2002-US3987 W 20020208

ED Entered STN: 29 Oct 2004

AB The invention relates to cultures or collections of strains which overexpress or underexpress gene products required for the proliferation of an organism. The invention also includes methods for identifying the target on which a compound which inhibits the proliferation of an organism acts and methods for identifying the extent to which a strain is present in a culture or collection of strains. Thus, a culture is obtained comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation. The culture is contacted with a sufficient concentration of an agent to inhibit the proliferation of strains which do not overexpress the gene product on which the agent acts, such that strains which overexpress the gene product on which the agent acts proliferate more rapidly than strains which do not overexpress said gene product on which the agent acts. The gene product which is overexpressed in a strain which proliferates more rapidly in the culture is then identified. Expression levels of gene transcripts are determined using hybridization and/or amplification methods standard to the art.

Genes required for cellular proliferation of microbial organisms are identified by antisense RNA technol. Nucleotide sequences are provided for nucleic acid fragments whose expression results in detrimental effects on proliferation of *Escherichia coli*, *Staphylococcus aureus*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, or *Enterococcus faecalis*. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 775411-62-6 775415-96-8

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; target gene product identification for microbial cell proliferation-inhibiting compds.)

L20 ANSWER 11 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:372714 CAPLUS
 DOCUMENT NUMBER: 140:387047
 TITLE: Human polynucleotides and polypeptides associated with
 the NF- κ B pathway and their diagnostic and
 therapeutic applications
 INVENTOR(S): Carman, Julie; Feder, John N.; Nadler, Steven G.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 474 pp., Cont.-in-part of U.S.
 Ser. No. 126,103.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004086896	A1	20040506	US 2003-431096	20030507
US 2003224486	A1	20031204	US 2002-126103	20020419
WO 2004100886	A2	20041125	WO 2004-US14279	20040506
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1628629	A2	20060301	EP 2004-751601	20040506
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.:				
			US 2001-284962P	P 20010419
			US 2001-286645P	P 20010426
			US 2002-346986P	P 20020109
			US 2002-126103	A2 20020419
			US 2003-431096	A 20030507
			WO 2004-US14279	W 20040506

ED Entered STN: 07 May 2004

AB The present invention provides polynucleotides encoding
 NF- κ B-associated polypeptides, fragments and homologs thereof. The
 polynucleotides and polypeptides were identified based upon their
 differential expression upon the administration of a known NF- κ B
 peptide inhibitor, and are believed to represent either direct, or
 indirect, participating members of the NF- κ B pathway. Also provided
 are vectors, host cells, antibodies, and recombinant and synthetic methods
 for producing said polypeptides. The invention further relates to
 diagnostic and therapeutic methods for applying these NF- κ B-associated
 polypeptides to the diagnosis, treatment, and/or prevention of various
 diseases and/or disorders related to these polypeptides. The invention
 further relates to screening methods for identifying agonists and
 antagonists of the polynucleotides and polypeptides of the present
 invention.

IT 685914-31-2

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP
 (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (amino acid sequence; human polynucleotides and polypeptides associated

with the NF- κ B pathway and their diagnostic and therapeutic applications)

L20 ANSWER 12 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:355040 CAPLUS

DOCUMENT NUMBER: 140:351718

TITLE: Human nucleic acids and their encoded proteins and their diagnostic and therapeutic uses

INVENTOR(S): Williams, Lewis T.; Chu, Keting; Lee, Ernestine; Hestir, Kevin; Beaurang, Pierre Alvaro; Behrens, Dirk; Halenbeck, Robert Forgan; Huang, Min Mei; Kothakota, Srinivas; Haishan, Lin; Linnemann, Thomas; Pierce, Kristen; Wang, Yan; Wong, Justin G. P.; Wu, Ge; Zhang, Hongbing

PATENT ASSIGNEE(S): Five Prime Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 428 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 19

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035732	A2	20040429	WO 2003-US26780	20030828
WO 2004035732	A3	20060126		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003294217	A1	20040504	AU 2003-294217	20030828
PRIORITY APPLN. INFO.:			US 2002-406576P	P 20020829
			US 2002-406579P	P 20020829
			US 2002-406585P	P 20020829
			US 2002-406588P	P 20020829
			US 2002-406608P	P 20020829
			US 2002-406611P	P 20020829
			US 2002-406612P	P 20020829
			US 2002-406616P	P 20020829
			US 2002-406640P	P 20020829
			US 2002-406642P	P 20020829
			US 2002-406646P	P 20020829
			US 2002-406653P	P 20020829
			US 2002-406655P	P 20020829
			US 2002-406666P	P 20020829
			US 2002-410946P	P 20020917
			US 2002-410947P	P 20020917
			US 2002-410948P	P 20020917
			US 2002-410949P	P 20020917
			US 2002-410953P	P 20020917
			US 2002-410957P	P 20020917
			US 2002-410958P	P 20020917
			US 2002-410959P	P 20020917
			US 2002-410960P	P 20020917

US 2002-410961P	P	20020917
US 2002-410962P	P	20020917
US 2002-411019P	P	20020917
US 2002-411022P	P	20020917
US 2002-411023P	P	20020917
US 2002-411024P	P	20020917
US 2002-411035P	P	20020917
US 2002-411037P	P	20020917
US 2002-411041P	P	20020917
US 2002-411045P	P	20020917
US 2002-411046P	P	20020917
US 2002-411048P	P	20020917
US 2002-411052P	P	20020917
US 2002-411055P	P	20020917
US 2002-411073P	P	20020917
US 2002-411082P	P	20020917
US 2002-411101P	P	20020917
US 2002-411111P	P	20020917
US 2003-471336P	P	20030519
US 2003-472420P	P	20030522
US 2003-472430P	P	20030522
US 2003-476609P	P	20030609
US 2003-476641P	P	20030609
US 2003-485218P	P	20030708
US 2003-485223P	P	20030708
US 2003-485224P	P	20030708
US 2003-485325P	P	20030708
US 2003-486446P	P	20030714
US 2003-486480P	P	20030714
US 2003-486891P	P	20030715
US 2003-486960P	P	20030715
US 2003-493341P	P	20030808
US 2003-493370P	P	20030808
US 2003-493573P	P	20030808
US 2003-493577P	P	20030808

ED Entered STN: 30 Apr 2004

AB The invention provides 1231 novel cDNAs isolated from human tissues, and their encoded polypeptides, related nucleic acid and polypeptide compns., and related modulators, such as antibodies and small mol. modulators. The invention also provides methods to make and use these polynucleotides, polypeptides, related compns., and modulators. These methods include diagnostic, prophylactic, and therapeutic applications. The compns. and methods of the invention are useful in treating proliferative disorders, e.g., cancers, and inflammatory, immune, bacterial, and viral disorders.

IT 681877-57-6P 681877-58-7P

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; human nucleic acids and their encoded proteins and their diagnostic and therapeutic uses)

L20 ANSWER 13 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:892912 CAPLUS

DOCUMENT NUMBER: 139:359866

TITLE: Bacillus licheniformis mutants with improved production of heterologous proteins by reducing the amount of contaminant secreted native polypeptide(s)

INVENTOR(S): Andersen, Jens Tonne; Jorgensen, Steen Troels; Rasmussen, Michael Dolbjerg; Olsen, Peter Bjarke;

PATENT ASSIGNEE(S): Clausen, Ib Groth
 SOURCE: Novozymes A/S, Den.
 PCT Int. Appl., 422 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093453	A2	20031113	WO 2003-DK198	20030325
WO 2003093453	A3	20040513		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003214034	A1	20031117	AU 2003-214034	20030325
EP 1497429	A2	20050119	EP 2003-709679	20030325
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1659283	A	20050824	CN 2003-813403	20030325
US 2005244922	A1	20051103	US 2004-510386	20041004
PRIORITY APPLN. INFO.:			DK 2002-534	A 20020410
			WO 2003-DK198	W 20030325

ED Entered STN: 14 Nov 2003

AB A *Bacillus licheniformis* mutant host cell derived from a parent *B. licheniformis* host cell is provided in which the mutant host cell is mutated in one or more gene(s) encoding one or more of 122 secreted polypeptide(s). The mutant host cell secretes $\geq 5\%$ less of the one or more secreted polypeptide(s) than the parent host cell, when they are cultivated under comparable conditions. This reduces the necessary product purification required when producing heterologous products of interest in a *B. licheniformis* host cell. Production in a mutant host cell of the invention provides a culture medium with far fewer contaminants, and this in turn makes it much easier to purify the product of interest from the culture medium to the point where certain previously required steps may be completely eliminated from the production process. A vector and protocols are designed to allow deletion of the entire open reading frame of the gene encoding a small extracellular protein from *B. licheniformis*.

IT 622412-43-5

RL: PRP (Properties); REM (Removal or disposal); PROC (Process)
 (amino acid sequence; *Bacillus licheniformis* mutants with improved production of heterologous proteins by reducing the amount of contaminant secreted native polypeptide(s))

L20 ANSWER 14 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:711169 CAPLUS

DOCUMENT NUMBER: 139:208896

TITLE: Nucleic acid and amino acid sequences relating to
 Enterococcus faecalis for diagnostics and therapeutics

INVENTOR(S): Doucette-Stamm, Lynn A.; Bush, David

PATENT ASSIGNEE(S): USA

SOURCE: U.S., 193 pp.

CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6617156	B1	20030909	US 1998-134000	19980813
			US 1997-55778P	P 19970815

PRIORITY APPLN. INFO.:

ED Entered STN: 10 Sep 2003

AB The invention provides 3405 isolated genomic nucleic acid and their encoded polypeptide sequences derived from Enterococcus faecalis (strain 14336) that are useful in diagnosis and therapy of pathol. conditions. Antibodies against the polypeptides, and methods for the production of the polypeptides are provided. The invention also provides methods for the detection, prevention, and treatment of pathol. conditions resulting from bacterial infection.

IT 585651-26-9 585657-03-0

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS-AVAILABLE IN THE RE-FORMAT

L20 ANSWER 15 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:697220 CAPLUS

DOCUMENT NUMBER: 139:192571

TITLE: Nucleic acid and encoded amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics

INVENTOR(S): Breton, Gary L.; Osborne, Mark

PATENT ASSIGNEE(S): Genome Therapeutics Corporation, USA

SOURCE: U.S., 932 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6610836	B1	20030826	US 2000-489039	20000127
			US 1999-117747P	P 19990129

PRIORITY APPLN. INFO.:

ED Entered STN: 07 Sep 2003

AB The invention provides 7171 isolated polypeptide and 7171 genomic nucleic acid sequences derived from Klebsiella pneumoniae strain 93,19097 (ATCC 202080) that are useful in diagnosis and therapy of pathol. conditions. The nucleotide sequences include those of two naturally occurring plasmids in K. pneumoniae. Antibodies against the polypeptides, and methods for the production of recombinant polypeptides are also provided. The invention also provides methods for the detection, prevention, and treatment of pathol. conditions resulting from bacterial infection. [This abstract record is one of four records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 581924-74-5 581930-51-0

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; nucleic acid and encoded amino acid sequences relating to *Klebsiella pneumoniae* for diagnostics and therapeutics)

L20 ANSWER 16 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:697219 CAPLUS

DOCUMENT NUMBER: 139:192570

TITLE: Nucleic acid and encoded amino acid sequences relating to *Klebsiella pneumoniae* for diagnostics and therapeutics

INVENTOR(S): Breton, Gary L.; Osborne, Mark

PATENT ASSIGNEE(S): Genome Therapeutics Corporation, USA

SOURCE: U.S., 932 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6610836	B1	20030826	US 2000-489039	20000127
PRIORITY APPLN. INFO.:			US 1999-117747P	P 19990129

ED Entered STN: 07 Sep 2003

AB The invention provides 7171 isolated polypeptide and 7171 genomic nucleic acid sequences derived from *Klebsiella pneumoniae* strain 93,19097 (ATCC 202080) that are useful in diagnosis and therapy of pathol. conditions. The nucleotide sequences include those of two naturally occurring plasmids in *K. pneumoniae*. Antibodies against the polypeptides, and methods for the production of recombinant polypeptides are also provided. The invention also provides methods for the detection, prevention, and treatment of pathol. conditions resulting from bacterial infection. [This abstract record is one of four records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 581877-64-7

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; nucleic acid and encoded amino acid sequences relating to *Klebsiella pneumoniae* for diagnostics and therapeutics)

L20 ANSWER 17 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:609959 CAPLUS

DOCUMENT NUMBER: 139:160827

TITLE: Polynucleotides which are of nature B2/D+ A- and which are isolated from *Escherichia coli*, and biological uses of these polynucleotides and of their polypeptides for clinical detection, diagnostic, and therapeutic applications

INVENTOR(S): Bingen, Edouard; Bonacorsi, Stephane; Clermont, Olivier; Nassif, Xavier; Tinsley, Colin

PATENT ASSIGNEE(S): Fr.

SOURCE: U.S. Pat. Appl. Publ., 580 pp., Cont.-in-part of Appl. No. PCT/EP01/03445.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 2003148324	A1	20030807	US 2002-238075	20020910
WO 2001066572	A2	20010913	WO 2001-EP3445	20010312
WO 2001066572	A3	20030501		
WO 2001066572	C2	20020815		

W: CA, JP, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, TR

PRIORITY APPLN. INFO.:

FR 2001-1449	A	20010202
WO 2001-EP3445	A2	20010312
FR 2000-3145	A	20000310

ED Entered STN: 08 Aug 2003

AB The present invention relates to DNA products which are of nature B2+ A-, isolated from Escherichia coli, and to their biol. applications, in particular their medical (therapeutic, vaccine and diagnostic) and biotechnol. applications. In the present application, the expression "of nature B2+ A-" is intended to mean presence at a frequency greater than 10% among the E. coli strains of group B2 of the ECOR collection, and at a frequency of less than 10% among the strains of group A of the same collection. Libraries of DNA fragments of the strain C5 of group B2, which are not found in the genome of E. coli of group A (ECOR4 and ECOR15), were produced using the techniques of subtractive hybridization and representational difference anal. These fragments make up genes which participate specifically in the systemic and non-diarrheal extra-intestinal development of E. coli in humans and animals. These fragments and the genes which bear them can be used as active principles (in the form of naked DNA placed under the control of a eukaryotic promoter or in the form of DNA transfected into a cell) in a vaccine composition intended to prevent, alleviate, or combat the systemic and non-diarrheal development of E. coli in a human or animal extra-intestinal compartment. A phylogenetic determination PCR method which makes it possible to rapidly and easily distinguish the groups A, B1, B2 and D of the E. coli species with >99% precision is in particular described. Using two genes, chuA and yjaA, and a novel DNA fragment named TspE4.C2, the phylogenetic groups of 220 strains which had previously been assigned to phylogenetic groups determined using known methods were determined

IT 573735-22-5 573742-31-1

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; polynucleotides which are of nature B2/D+ A- and which are isolated from Escherichia coli, and biol. uses of these polynucleotides and of their polypeptides for clin. detection, diagnostic, and therapeutic applications)

L20 ANSWER 18 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:551621 CAPLUS

DOCUMENT NUMBER: 139:129924

TITLE: CRISSP method for detecting remote sequence homologs, human protein kinase sequences identified with the method, and diagnostic and drug screening uses

INVENTOR(S): Grigoriev, Igor Vyacheslavovich; Sudarsanam, Sucha

PATENT ASSIGNEE(S): Sugan Inc., USA

SOURCE: PCT Int. Appl., 491 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057841	A2	20030717	WO 2002-US41687	20021231
WO 2003057841	C1	20040401		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002364257	A1	20030724	AU 2002-364257	20021231
US 2004009549	A1	20040115	US 2002-334143	20021231
EP 1576087	A2	20050921	EP 2002-799335	20021231
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2006500004	T2	20060105	JP 2003-558143	20021231
WO 2004069154	A2	20040819	WO 2003-US2234	20030128
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003214893	A1	20040830	AU 2003-214893	20030128
PRIORITY APPLN. INFO.:			US 2001-343169P	P 20011231
			WO 2002-US41687	W 20021231
			WO 2003-US2234	A 20030128
ED	Entered STN:	18 Jul 2003		
AB	The present invention relates to novel methods for detecting remote polypeptide homologs comprising anal. of conserved secondary structure pattern in a protein family, and conserved active site amino acid residues. The anal. are used to identify conserved residues embedded into the secondary structure pattern (CRISSP), which are used to detect remote homologs of the referent protein family. The present invention also relates to human protein kinases and protein kinase-like enzymes, nucleotide sequences encoding the protein kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various protein kinase-related diseases and conditions. The CRISSP method has been applied to the human genome database and 87 novel kinase sequences have been identified. The partial or complete sequences of these kinases are provided together with their classification, predicted protein structure, and encoding nucleotide sequences. Through the use of a bioinformatics strategy, mammalian protein kinases have been identified and their protein structure predicted.			
IT	564490-86-4DP, subfragments are claimed			
	RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(amino acid sequence; CRISSP method for detecting remote sequence homologs, human protein kinase sequences identified with the method,			

and diagnostic and drug screening uses)

L20 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:508998 CAPLUS
 DOCUMENT NUMBER: 139:48271
 TITLE: Nucleic acid and protein sequences and expression system relating to Enterococcus faecium for diagnostics and therapeutics
 INVENTOR(S): Doucette-Stamm, Lynn A.; Bush, David
 PATENT ASSIGNEE(S): Genome Therapeutics Corporation, USA
 SOURCE: U.S., 243 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6583275	B1	20030624	US 1998-107532	19980630
US 6583275	B1	20030624	US 1998-107532	19980630
PRIORITY APPLN. INFO.:			US 1997-51571P	P 19970702
			US 1998-85598P	P 19980514
			US 1998-107532	A 19980630

ED Entered STN: 04 Jul 2003

AB The invention provides 3654 polypeptide and 3654 nucleic acid sequences derived from Enterococcus faecium that are useful in diagnosis and therapy of pathol. conditions, antibodies against the polypeptides, and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention, and treatment of pathol. conditions resulting from bacterial infection. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 543797-67-7

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; nucleic acid and protein sequences and expression system relating to Enterococcus faecium for diagnostics and therapeutics)

L20 ANSWER 20 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:434308 CAPLUS
 DOCUMENT NUMBER: 139:35063
 TITLE: CD83 gene products for manipulating cytokine levels and treating autoimmune disease, allergy, cancer and infection
 INVENTOR(S): Ramsdell, Fred; Proll, Sean C.; Staehling-Hampton, Karen; Appelby, Mark W.; Martinez, Leon Fernando Garcia
 PATENT ASSIGNEE(S): Celltech R & D, Inc., USA
 SOURCE: PCT Int. Appl., 158 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045318	A2	20030605	WO 2002-US37738	20021121

WO 2003045318 A3 20040916
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2466845 AA 20030605 CA 2002-2466845 20021121
AU 2002357759 A1 20030610 AU 2002-357759 20021121
EP 1480598 A2 20041201 EP 2002-792297 20021121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
JP 2005519586 T2 20050707 JP 2003-546823 20021121
WO 2004048552 A2 20040610 WO 2003-US38599 20031121
WO 2004048552 A3 20051201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003300817 A1 20040618 AU 2003-300817 20031121
US 2004185040 A1 20040923 US 2003-719642 20031121
EP 1572976 A2 20050914 EP 2003-812060 20031121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 2006083740 A1 20060420 US 2005-496284 20050930
PRIORITY APPLN. INFO.: US 2001-331958P P 20011121
US 2002-428130P P 20021121
WO 2002-US37738 W 20021121
US 2003-473279P P 20030522
WO 2003-US38599 W 20031121

ED Entered STN: 06 Jun 2003

AB The invention provides methods for modulating cytokine levels, GM-CSF levels and the immune system using CD83 nucleic acids, CD83 polypeptides, anti-CD83 antibodies and factors that influence CD83 activity or expression. The invention also provides mice having a mutant CD83 gene and mice having a transgenic CD83 gene, which are useful for defining the role of CD83 in the immune system and for identifying compds. that can modulate CD83 and the immune system.

IT 540550-36-5P 540550-40-1P 540550-46-7P
540550-50-3P 540550-65-0P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; CD83 nucleic acids, polypeptides and antibodies for manipulating cytokine levels and treating autoimmune disease, allergy, cancer and infection)

L20 ANSWER 21 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:381677 CAPLUS
DOCUMENT NUMBER: 138:349762

TITLE: Nucleic acid and amino acid sequences relating to
Acinetobacter baumannii for diagnostics and
therapeutics
INVENTOR(S): Breton, Gary; Bush, David
PATENT ASSIGNEE(S): Genome Therapeutics Corporation, USA
SOURCE: U.S., 328 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6562958	B1	20030513	US 1999-328352	19990604
US 6562958	B1	20030513	US 1999-328352	19990604
PRIORITY APPLN. INFO.:			US 1998-88701P	P 19980609
			US 1999-328352	A 19990604

ED Entered STN: 20 May 2003

AB The invention provides 4126 nucleic acid sequences derived from a genomic library of Acinetobacter baumannii strain 15839, as well as the derived open reading frames and protein-coding sequences. These sequences are useful in diagnosis and therapy of pathol. conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathol. conditions resulting from bacterial infection. [This abstract record is one of 2 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 518382-28-0

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics)

L20 ANSWER 22 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:326646 CAPLUS

DOCUMENT NUMBER: 138:298935

TITLE: Nucleic acid and amino acid sequences relating to
Pseudomonas aeruginosa for diagnostics and
therapeutics

INVENTOR(S): Rubenfield, Marc J.; Nolling, Jork; Deloughery, Craig;
Bush, David

PATENT ASSIGNEE(S): Genome Therapeutics Corporation, USA

SOURCE: U.S., 455 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6551795	B1	20030422	US 1999-252991	19990218
US 6551795	B1	20030422	US 1999-252991	19990218
PRIORITY APPLN. INFO.:			US 1998-74788P	P 19980218
			US 1998-94190P	P 19980727
			US 1999-252991	A 19990218

ED Entered STN: 30 Apr 2003

AB The invention provides 16,571 isolated polypeptide and their encoding

nucleic acid sequences derived from *Pseudomonas aeruginosa* strain 19804 (ATCC #202004) that are useful in diagnosis and therapy of pathol. conditions, antibodies against the polypeptides, and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathol. conditions resulting from bacterial infection. [This abstract record is one of eight records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 509212-38-8 509226-42-0

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; nucleic acid and amino acid sequences relating to *Pseudomonas aeruginosa* for diagnostics and therapeutics)

L20 ANSWER 23 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:326645 CAPLUS

DOCUMENT NUMBER: 138:298934

TITLE: Nucleic acid and amino acid sequences relating to *Pseudomonas aeruginosa* for diagnostics and therapeutics

INVENTOR(S): Rubenfield, Marc J.; Nolling, Jork; Deloughery, Craig; Bush, David

PATENT ASSIGNEE(S): Genome Therapeutics Corporation, USA

SOURCE: U.S., 455 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6551795	B1	20030422	US 1999-252991	19990218
US 6551795	B1	20030422	US 1999-252991	19990218
PRIORITY APPLN. INFO.:			US 1998-74788P	P 19980218
			US 1998-94190P	P 19980727
			US 1999-252991	A 19990218

ED Entered STN: 30 Apr 2003

AB The invention provides 16,571 isolated polypeptide and their encoding nucleic acid sequences derived from *Pseudomonas aeruginosa* strain 19804 (ATCC #202004) that are useful in diagnosis and therapy of pathol. conditions, antibodies against the polypeptides, and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathol. conditions resulting from bacterial infection. [This abstract record is one of eight records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 509169-05-5 509196-08-1

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; nucleic acid and amino acid sequences relating to *Pseudomonas aeruginosa* for diagnostics and therapeutics)

L20 ANSWER 24 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:326641 CAPLUS

DOCUMENT NUMBER: 138:298932

TITLE: Nucleic acid and amino acid sequences relating to *Pseudomonas aeruginosa* for diagnostics and therapeutics

INVENTOR(S): Rubenfield, Marc J.; Nolling, Jork; Deloughery, Craig;

Bush, David
 PATENT ASSIGNEE(S): Genome Therapeutics Corporation, USA
 SOURCE: U.S., 455 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 8
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6551795	B1	20030422	US 1999-252991	19990218
US 6551795	B1	20030422	US 1999-252991	19990218
PRIORITY APPLN. INFO.:			US 1998-74788P	P 19980218
			US 1998-94190P	P 19980727
			US 1999-252991	A 19990218

ED Entered STN: 30 Apr 2003

AB The invention provides 16,571 isolated polypeptide and their encoding nucleic acid sequences derived from *Pseudomonas aeruginosa* strain 19804 (ATCC #202004) that are useful in diagnosis and therapy of pathol. conditions, antibodies against the polypeptides, and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathol. conditions resulting from bacterial infection. [This abstract record is one of eight records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 508404-55-5

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; nucleic acid and amino acid sequences relating to *Pseudomonas aeruginosa* for diagnostics and therapeutics)

L20 ANSWER 25 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:948944 CAPLUS

DOCUMENT NUMBER: 138:50913

TITLE: Sequence of the genome of *Streptococcus agalactiae* and application to the development of vaccines and diagnostic tools and for identification of therapeutic targets

INVENTOR(S): Glaser, Philippe; Rusniok, Christophe; Chevalier, Fabien; Frangeul, Lionel; Lalioui, Lila; Zouine, Mohammed; Couve, Elisabeth; Buchrieser, Carmen; Poyart, Claire; Trieu, Cuot Patrick

PATENT ASSIGNEE(S): Institut Pasteur, Fr.

SOURCE: Fr. Demande, 2687 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2824074	A1	20021031	FR 2001-5642	20010426
WO 2002092818	A2	20021121	WO 2002-IB3059	20020426
WO 2002092818	A3	20030828		
WO 2002092818	C1	20040304		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
 GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

FR 2001-5642

A 20010426

ED Entered STN: 16 Dec 2002

AB The nearly complete sequence of the genome of *Streptococcus agalactiae* strain CIP 8245 (ATCC 12403) was determined by shotgun sequencing. The 2.2-Mb chromosome is represented by 138 contigs, and a plasmid genome comprising 45 kbp by a single contig. Addnl., the sequences of 2205 proteins encoded by open reading frames within the genome are provided. Characterization of the genome and its encoded proteome provide the basis for detection and/or amplification of *Streptococcus* bacteria, and in particular *S. agalactiae*, cloning and expression vectors for genetic transformation, antibodies for use in immunoassays of *Streptococcus* bacteria, and development of pharmaceuticals and/or vaccines for inhibition of *S. agalactiae* infection of animals or humans.

IT 478896-49-0 479012-16-3

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (amino acid sequence; sequence of the genome of *Streptococcus agalactiae* and application to the development of vaccines and diagnostic tools and for identification of therapeutic targets)

L20 ANSWER 26 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:906293 CAPLUS

DOCUMENT NUMBER: 138:8311

TITLE: *Staphylococcus aureus* proteins and nucleic acids and their diagnostic and therapeutic uses for staphylococcal infections

INVENTOR(S): Masignani, Vega; Mora, Marirosa; Scarselli, Maria

PATENT ASSIGNEE(S): Chiron Spa, Italy

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094868	A2	20021128	WO 2002-IB2637	20020327
WO 2002094868	A3	20030918		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2440368	AA	20021128	CA 2002-2440368	20020327
EP 1373310	A2	20040102	EP 2002-749141	20020327
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002077183	A2	20021003	WO 2002-XP9107	20020321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002061569	A1	20020523	US 2001-815242	20010321
WO 2002077183	A2	20021003	WO 2002-US9107	20020321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2001-815242	A 20010321
			US 2001-948993	A 20010906
			US 2001-342923P	P 20011025
			US 2002-72851	A 20020208
			US 2002-362699P	P 20020306
			WO 2002-US9107	A 20020321
			US 2000-191078P	P 20000321
			US 2000-206848P	P 20000523
			US 2000-207727P	P 20000526
			US 2000-242578P	P 20001023
			US 2000-253625P	P 20001127
			US 2000-257931P	P 20001222
			US 2001-269308P	P 20010216
ED	Entered STN: 14 Oct 2002			
AB	<p>The sequences of antisense nucleic acids which inhibit the proliferation of prokaryotes are disclosed. Thus, 6213 nucleic acid fragments are identified for which expression inhibits proliferation or is required for proliferation in <i>Enterococcus faecalis</i>, <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Pseudomonas aeruginosa</i>, <i>Salmonella typhimurium</i>, and <i>Staphylococcus aureus</i>. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the expressed proteins, and to use those expressed proteins as a screen to isolate candidate mols. for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than <i>Staphylococcus aureus</i>, <i>Salmonella typhimurium</i>, <i>Klebsiella pneumoniae</i>, and <i>Pseudomonas aeruginosa</i>. The invention provides 38,184 such proliferation-required gene sequences (plus their encoded protein sequences). The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in other organisms. [This abstract record is one of twenty records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]</p>			
IT	477132-31-3 477134-44-4			
	RL: BSU (Biological study, unclassified); BUU (Biological use,			

unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening)

L20 ANSWER 29 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:781492 CAPLUS

DOCUMENT NUMBER: 138:1096

TITLE: Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening

INVENTOR(S): Wang, Liangus; Zamudio, Carlos; Malone, Cheryl; Haselbeck, Robert; Ohlsen, Kari L.; Zyskind, Judith W.; Wall, Daniel; Trawick, John D.; Carr, Grant J.; Yamamoto, Robert; Forsyth, R. Allyn; Xu, H. Howard

PATENT ASSIGNEE(S): Elitra Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 1766 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002077183	A2	20021003	WO 2002-XO9107	20020321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002061569	A1	20020523	US 2001-815242	20010321
WO 2002077183	A2	20021003	WO 2002-US9107	20020321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

US 2001-815242	A	20010321
US 2001-948993	A	20010906
US 2001-342923P	P	20011025
US 2002-72851	A	20020208
US 2002-362699P	P	20020306
WO 2002-US9107	A	20020321
US 2000-191078P	P	20000321
US 2000-206848P	P	20000523
US 2000-207727P	P	20000526
US 2000-242578P	P	20001023
US 2000-253625P	P	20001127
US 2000-257931P	P	20001222
US 2001-269308P	P	20010216

ED Entered STN: 14 Oct 2002

AB The sequences of antisense nucleic acids which inhibit the proliferation of prokaryotes are disclosed. Thus, 6213 nucleic acid fragments are identified for which expression inhibits proliferation or is required for proliferation in *Enterococcus faecalis*, *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, and *Staphylococcus aureus*. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the expressed proteins, and to use those expressed proteins as a screen to isolate candidate mols. for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than *Staphylococcus aureus*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. The invention provides 38,184 such proliferation-required gene sequences (plus their encoded protein sequences). The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in other organisms. [This abstract record is one of twenty records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 477096-03-0 477098-69-4 477111-51-6

477120-68-6 477127-03-0

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening)

L20 ANSWER 30 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:781491 CAPLUS

DOCUMENT NUMBER: 138:1095

TITLE: Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening

INVENTOR(S): Wang, Liangus; Zamudio, Carlos; Malone, Cheryl; Haselbeck, Robert; Ohlsen, Kari L.; Zyskind, Judith W.; Wall, Daniel; Trawick, John D.; Carr, Grant J.; Yamamoto, Robert; Forsyth, R. Allyn; Xu, H. Howard

PATENT ASSIGNEE(S): Elitra Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 1766 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002077183	A2	20021003	WO 2002-XN9107	20020321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,			

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2002061569 A1 20020523 US 2001-815242 20010321
 WO 2002077183 A2 20021003 WO 2002-US9107 20020321

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2001-815242	A	20010321
US 2001-948993	A	20010906
US 2001-342923P	P	20011025
US 2002-72851	A	20020208
US 2002-362699P	P	20020306
WO 2002-US9107	A	20020321
US 2000-191078P	P	20000321
US 2000-206848P	P	20000523
US 2000-207727P	P	20000526
US 2000-242578P	P	20001023
US 2000-253625P	P	20001127
US 2000-257931P	P	20001222
US 2001-269308P	P	20010216

ED Entered STN: 14 Oct 2002

AB The sequences of antisense nucleic acids which inhibit the proliferation of prokaryotes are disclosed. Thus, 6213 nucleic acid fragments are identified for which expression inhibits proliferation or is required for proliferation in *Enterococcus faecalis*, *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, and *Staphylococcus aureus*. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the expressed proteins, and to use those expressed proteins as a screen to isolate candidate mols. for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than *Staphylococcus aureus*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. The invention provides 38,184 such proliferation-required gene sequences (plus their encoded protein sequences). The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in other organisms. [This abstract record is one of twenty records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 477074-36-5

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening)

L20 ANSWER 31 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:781490 CAPLUS

DOCUMENT NUMBER: 138:1094

TITLE: Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and

antibiotic screening
 INVENTOR(S): Wang, Liangus; Zamudio, Carlos; Malone, Cheryl;
 Haselbeck, Robert; Ohlsen, Kari L.; Zyskind, Judith
 W.; Wall, Daniel; Trawick, John D.; Carr, Grant J.;
 Yamamoto, Robert; Forsyth, R. Allyn; Xu, H. Howard
 PATENT ASSIGNEE(S): Elitra Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 1766 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 22
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002077183	A2	20021003	WO 2002-XM9107	20020321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002061569	A1	20020523	US 2001-815242	20010321
WO 2002077183	A2	20021003	WO 2002-US9107	20020321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2001-815242	A 20010321
			US 2001-948993	A 20010906
			US 2001-342923P	P 20011025
			US 2002-72851	A 20020208
			US 2002-362699P	P 20020306
			WO 2002-US9107	A 20020321
			US 2000-191078P	P 20000321
			US 2000-206848P	P 20000523
			US 2000-207727P	P 20000526
			US 2000-242578P	P 20001023
			US 2000-253625P	P 20001127
			US 2000-257931P	P 20001222
			US 2001-269308P	P 20010216

ED Entered STN: 14 Oct 2002

AB The sequences of antisense nucleic acids which inhibit the proliferation of prokaryotes are disclosed. Thus, 6213 nucleic acid fragments are identified for which expression inhibits proliferation or is required for proliferation in *Enterococcus faecalis*, *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, and *Staphylococcus aureus*. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the expressed proteins, and

to use those expressed proteins as a screen to isolate candidate mols. for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than *Staphylococcus aureus*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. The invention provides 38,184 such proliferation-required gene sequences (plus their encoded protein sequences). The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in other organisms. [This abstract record is one of twenty records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 477050-99-0

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening)

L20 ANSWER 32 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:781489 CAPLUS

DOCUMENT NUMBER: 138:1093

TITLE: Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening

INVENTOR(S): Wang, Liangus; Zamudio, Carlos; Malone, Cheryl; Haselbeck, Robert; Ohlsen, Kari L.; Zyskind, Judith W.; Wall, Daniel; Trawick, John D.; Carr, Grant J.; Yamamoto, Robert; Forsyth, R. Allyn; Xu, H. Howard

PATENT ASSIGNEE(S): Elitra Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 1766 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002077183	A2	20021003	WO 2002-XL9107	20020321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002061569	A1	20020523	US 2001-815242	20010321
WO 2002077183	A2	20021003	WO 2002-US9107	20020321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

US 2001-815242	A	20010321
US 2001-948993	A	20010906
US 2001-342923P	P	20011025
US 2002-72851	A	20020208
US 2002-362699P	P	20020306
WO 2002-US9107	A	20020321
US 2000-191078P	P	20000321
US 2000-206848P	P	20000523
US 2000-207727P	P	20000526
US 2000-242578P	P	20001023
US 2000-253625P	P	20001127
US 2000-257931P	P	20001222
US 2001-269308P	P	20010216

ED Entered STN: 14 Oct 2002

AB The sequences of antisense nucleic acids which inhibit the proliferation of prokaryotes are disclosed. Thus, 6213 nucleic acid fragments are identified for which expression inhibits proliferation or is required for proliferation in *Enterococcus faecalis*, *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, and *Staphylococcus aureus*. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the expressed proteins, and to use those expressed proteins as a screen to isolate candidate mols. for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than *Staphylococcus aureus*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. The invention provides 38,184 such proliferation-required gene sequences (plus their encoded protein sequences). The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in other organisms. [This abstract record is one of twenty records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 476984-42-6 476990-25-7 477012-17-2

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening)

L20 ANSWER 33 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:781488 CAPLUS

DOCUMENT NUMBER: 138:1092

TITLE: Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening

INVENTOR(S): Wang, Liangus; Zamudio, Carlos; Malone, Cheryl; Haselbeck, Robert; Ohlsen, Kari L.; Zyskind, Judith W.; Wall, Daniel; Trawick, John D.; Carr, Grant J.; Yamamoto, Robert; Forsyth, R. Allyn; Xu, H. Howard

PATENT ASSIGNEE(S): Elitra Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 1766 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002077183	A2	20021003	WO 2002-XK9107	20020321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002061569	A1	20020523	US 2001-815242	20010321
WO 2002077183	A2	20021003	WO 2002-US9107	20020321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:

US 2001-815242	A	20010321
US 2001-948993	A	20010906
US 2001-342923P	P	20011025
US 2002-72851	A	20020208
US 2002-362699P	P	20020306
WO 2002-US9107	A	20020321
US 2000-191078P	P	20000321
US 2000-206848P	P	20000523
US 2000-207727P	P	20000526
US 2000-242578P	P	20001023
US 2000-253625P	P	20001127
US 2000-257931P	P	20001222
US 2001-269308P	P	20010216

ED Entered STN: 14 Oct 2002

AB The sequences of antisense nucleic acids which inhibit the proliferation of prokaryotes are disclosed. Thus, 6213 nucleic acid fragments are identified for which expression inhibits proliferation or is required for proliferation in *Enterococcus faecalis*, *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, and *Staphylococcus aureus*. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the expressed proteins, and to use those expressed proteins as a screen to isolate candidate mols. for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than *Staphylococcus aureus*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. The invention provides 38,184 such proliferation-required gene sequences (plus their encoded protein sequences). The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in other organisms. [This abstract record is one of twenty records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints].

IT 476964-99-5

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening)

L20 ANSWER 34 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:781487 CAPLUS

DOCUMENT NUMBER: 138:1091

TITLE: Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening

INVENTOR(S): Wang, Liangus; Zamudio, Carlos; Malone, Cheryl; Haselbeck, Robert; Ohlsen, Kari L.; Zyskind, Judith W.; Wall, Daniel; Trawick, John D.; Carr, Grant J.; Yamamoto, Robert; Forsyth, R. Allyn; Xu, H. Howard

PATENT ASSIGNEE(S): Elitra Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 1766 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002077183	A2	20021003	WO 2002-XJ9107	20020321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002061569	A1	20020523	US 2001-815242	20010321
WO 2002077183	A2	20021003	WO 2002-US9107	20020321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2001-815242	A 20010321
			US 2001-948993	A 20010906
			US 2001-342923P	P 20011025
			US 2002-72851	A 20020208
			US 2002-362699P	P 20020306
			WO 2002-US9107	A 20020321
			US 2000-191078P	P 20000321
			US 2000-206848P	P 20000523
			US 2000-207727P	P 20000526
			US 2000-242578P	P 20001023
			US 2000-253625P	P 20001127
			US 2000-257931P	P 20001222

US 2001-269308P

P 20010216

ED Entered STN: 14 Oct 2002

AB The sequences of antisense nucleic acids which inhibit the proliferation of prokaryotes are disclosed. Thus, 6213 nucleic acid fragments are identified for which expression inhibits proliferation or is required for proliferation in *Enterococcus faecalis*, *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, and *Staphylococcus aureus*. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the expressed proteins, and to use those expressed proteins as a screen to isolate candidate mols. for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than *Staphylococcus aureus*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. The invention provides 38,184 such proliferation-required gene sequences (plus their encoded protein sequences). The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in other organisms. [This abstract record is one of twenty records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints].

IT 476919-75-2

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening)

L20 ANSWER 35 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:754696 CAPLUS

DOCUMENT NUMBER: 137:293520

TITLE: Antibody-containing sera for identifying Pathogenic and commensal bacteria antigens as vaccines

INVENTOR(S): Robinson, Andrew; Gorringe, Andrew Richard; Hudson, Michael John; Bracegirdle, Philippa; West, David McKay; Oliver, Kerry Jane; Kroll, John Simon; Langford, Paul Richard

PATENT ASSIGNEE(S): Microbiological Research Authority, UK; Imperial College Innovations Limited

SOURCE: PCT Int. Appl., 310 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002077648	A2	20021003	WO 2002-GB1399	20020322
WO 2002077648	A3	20031231		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,			

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

CN 1599751 A 20050323 CN 2002-805451 20020222

US 2004197896 A1 20041007 US 2004-468356 20040412

PRIORITY APPLN. INFO.: US 2001-270123P P 20010222

WO 2002-IB1973 W 20020222

ED Entered STN: 27 Sep 2002

AB The present invention is directed to a method of selection of purified nucleotide sequences or polynucleotides encoding proteins or part of proteins carrying at least an essential function for the survival or the virulence of mycobacterium species. The method comprises first aligning the genomic sequence of a first mycobacterium species on a genomic sequence of a second mycobacterium species. Then select a polynucleotide sequence highly conserved in both genomes with no counterparts in other bacterial genomic sequences and which corresponds to an essential gene for the survival or the virulence of the mycobacterium species. Optionally, the selected polynucleotide may be tested for its capacity of virulence or involvement in survival based on the activation or inactivation of said polynucleotide in a bacterial host, or testing being based on the activity of the product of expression of the polynucleotide in vivo or in vitro. This comparative genomic anal. is demonstrated with the genome of M. tuberculosis aligned on the genome sequence of M. leprae. Six hundred forty-four M. tuberculosis and M. leprae marker polypeptides are identified. The proteins are of use in diagnostic detection of infection by mycobacteria using standard electrophoresis or immunoassay techniques.

IT 461750-67-4

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(amino acid sequence; comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses)

L20 ANSWER 37 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:575103 CAPLUS

DOCUMENT NUMBER: 137:168250

TITLE: Hyperimmune serum-reactive antigens derived from expression libraries for treating or preventing pathogen infection, cancer, allergy, and autoimmune disease

INVENTOR(S): Meinke, Andreas; Nagy, Eszter; Von Ahsen, Uwe; Klade, Christoph; Henics, Tamas; Zauner, Wolfgang; Minh, Duc Bui; Vytvytska, Oresta; Etz, Hildegard; Dryla, Agnieszka; Weichhart, Thomas; Hafner, Martin; Tempelmaier, Brigitte

PATENT ASSIGNEE(S): Cistem Biotechnologies Gmbh, Austria; Intercell AG

SOURCE: PCT Int. Appl., 252 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059148	A2	20020801	WO 2002-EP546	20020121
WO 2002059148	C2	20021031		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2441551 AA 20021003 CA 2002-2441551 20020322
EP 1401865 A2 20040331 EP 2002-706996 20020322

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004534524 T2 20041118 JP 2002-575648 20020322
US 2004265328 A1 20041230 US 2004-472260 20040726

PRIORITY APPLN. INFO.: GB 2001-7219 A 20010322
WO 2002-GB1399 W 20020322

ED Entered STN: 04 Oct 2002

AB The invention provides methods of screening commensal and pathogenic bacteria for previously unidentified vaccine antigens, based upon identifying polypeptide antigens that bind to sera raised against commensal bacterial proteins. Also provided are vaccine compns. and methods of preparing vaccine compns. comprising the antigens identified by the screening methods. Antigens and uses thereof are also described.

IT 467261-10-5
RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; antibody-containing sera for identifying Pathogenic and commensal bacteria antigens as vaccines)

L20 ANSWER 36 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:736358 CAPLUS

DOCUMENT NUMBER: 137:258464

TITLE: Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses

INVENTOR(S): Cole, Stewart

PATENT ASSIGNEE(S): Institut Pasteur, Fr.

SOURCE: PCT Int. Appl., 874 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074903	A2	20020926	WO 2002-IB1973	20020222
WO 2002074903	A3	20031113		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2438279	AA	20020926	CA 2002-2438279	20020222
AU 2002302919	A1	20021003	AU 2002-302919	20020222
US 2003129601	A1	20030710	US 2002-80170	20020222
US 2004121322	A9	20040624		
EP 1401866	A2	20040331	EP 2002-730629	20020222
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

AT 200100130	A5	20021215	AT 2001-130	20010126
AT 410798	B	20030725		
CA 2436057	AA	20020801	CA 2002-2436057	20020121
EP 1355930	A2	20031029	EP 2002-716669	20020121
EP 1355930	B1	20051109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002007067	A	20040615	BR 2002-7067	20020121
JP 2004531476	T2	20041014	JP 2002-559450	20020121
CN 1649894	A	20050803	CN 2002-805765	20020121
AT 309268	E	20051115	AT 2002-716669	20020121
EP 1616876	A2	20060118	EP 2005-108422	20020121
EP 1616876	A3	20060412		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 527440	A	20060224	NZ 2002-527440	20020121
EP 1630172	A2	20060301	EP 2005-24214	20020121
EP 1630172	A3	20060503		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ES 2252438	T3	20060516	ES 2002-2716669	20020121
NO 2003003364	A	20030924	NO 2003-3364	20030725
ZA 2003005764	A	20040726	ZA 2003-5764	20030725
US 2005037444	A1	20050217	US 2004-470048	20040206
PRIORITY APPLN. INFO.:				
			AT 2001-130	A 20010126
			EP 2002-716669	A 20020121
			WO 2002-EP546	W 20020121

ED Entered STN: 02 Aug 2002

AB Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity that are suited for use as vaccines for treating related diseases in animals or humans. The method is characterized by providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity; providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity; screening said at least one expression library with said antibody preparation; identifying antigens which bind in said screening to antibodies in said antibody preparation; screening the identified antigens with individual antibody preps. from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity; identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preps. from said individual sera; and optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

IT 445315-39-9P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
 PRP (Properties); BIOL (Biological study); PREP (Preparation)
 (amino acid sequence; hyperimmune serum-reactive antigens derived from expression libraries for treating or preventing pathogen infection, cancer, allergy, and autoimmune disease)

L20 ANSWER 38 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:573395 CAPLUS
 DOCUMENT NUMBER: 137:104827
 TITLE: Genome sequence and protection from pathogenic
 microorganisms by strain NCC2705 of Bifidobacterium
 longum
 PATENT ASSIGNEE(S): Societe des Produits Nestle S.A., Switz.
 SOURCE: Eur. Pat. Appl., 80 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1227152	A1	20020731	EP 2001-102050	20010130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1227153	A2	20020731	EP 2002-1792	20020125
EP 1227153	A3	20020828		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2436049	AA	20020808	CA 2002-2436049	20020130
WO 2002060931	A2	20020808	WO 2002-EP955	20020130
WO 2002060931	A3	20021024		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002060932	A2	20020808	WO 2002-EP956	20020130
WO 2002060932	A3	20030605		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002247668	A1	20020812	AU 2002-247668	20020130
CA 2435664	AA	20020926	CA 2002-2435664	20020130
WO 2002074798	A2	20020926	WO 2002-EP958	20020130
WO 2002074798	A3	20021212		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,				

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002302360	A1	20021003	AU 2002-302360	20020130
EP 1358332	A2	20031105	EP 2002-718062	20020130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1360299	A2	20031112	EP 2002-729925	20020130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1500146	A	20040526	CN 2002-807287	20020130
CN 1518598	A	20040804	CN 2002-804318	20020130
JP 2004531229	T2	20041014	JP 2002-561500	20020130
JP 2004531245	T2	20041014	JP 2002-573806	20020130
US 2004126870	A1	20040701	US 2004-470565	20040107
US 2004115773	A1	20040617	US 2004-470559	20040203
PRIORITY APPLN. INFO.:			EP 2001-102050	A 20010130
			WO 2002-EP955	W 20020130
			WO 2002-EP956	W 20020130
			WO 2002-EP958	W 20020130

ED Entered STN: 02 Aug 2002

AB The present invention pertains to a novel microorganism of the genus *Bifidobacterium longum*, in particular to its genomic sequence and the nucleotide sequences encoding polypeptides of *Bifidobacterium NCC2705* (CNCM I-2618), which are secreted or specific or which are involved in the metabolism, in the replication process, and to polypeptides encoded by such sequences as well as to vectors including the said sequences and cells or non-human animals transformed with these nucleotide sequences and vectors, resp. The chromosomal genome of *B. longum NCC2705* comprises 2,256,628 base pairs. The invention also relates to 1997 transcriptional gene products of the *Bifidobacterium* genome and to methods of detecting these nucleic acids or polypeptides. The invention eventually comprises a data carrier comprising the nucleotide sequence and/or polypeptide sequence of *NCC2705* and also pertains to food and pharmaceutical compns. containing said microorganism for the prevention and/or treatment of diarrhea brought about by rotaviruses and pathogenic bacteria containing said *Bifidobacterium*.

IT 443409-85-6P 443410-96-6P

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); FFD (Food or feed use); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; genome sequence and protection from pathogenic microorganisms by strain *NCC2705* of *Bifidobacterium longum*)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 39 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:359274 CAPLUS

DOCUMENT NUMBER: 137:74442

TITLE: Nucleic acids and proteins from group B *Streptococcus agalactiae* and group A *Streptococcus pyogenes*

INVENTOR(S): Telford, John; Masignani, Vega; Margarit Y Ros, Immaculada; Grandi, Guido; Fraser, Claire; Tettelin, Herve

PATENT ASSIGNEE(S): Chiron S.P.A., Italy; The Institute for Genomic Research

SOURCE: PCT Int. Appl., 4525 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034771	A2	20020502	WO 2001-XA4789	20011029
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002034771	A2	20020502	WO 2001-GB4789	20011029
WO 2002034771	A3	20030116		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1671981	A2	20060621	EP 2006-75446	20011029
EP 1671981	A3	20060705		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003002739	A	20041117	ZA 2003-2739	20030408
PRIORITY APPLN. INFO.:			GB 2000-26333	A 20001027
			GB 2000-28727	A 20001124
			GB 2001-5640	A 20010307
			WO 2001-GB4789	W 20011029
			EP 2001-982584	A3 20011029
ED	Entered STN: 14 May 2002			
AB	<p>The invention provides proteins from group B streptococcus (<i>Streptococcus agalactiae</i>) and group A streptococcus (<i>Streptococcus pyogenes</i>), including amino acid sequences and the corresponding nucleotide sequences. The nucleotide sequence of the full genome of <i>S. agalactiae</i> strain 2603 V/R is provided as are 5483 protein-coding genes and the amino acid sequences of their protein products. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compns., and/or diagnostics. The proteins are also targets for antibiotics to treat or prevent bacterial infection, and in particular, streptococcal infection. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the document and publication constraints.]</p>			
IT	<p>440133-34-6</p> <p>RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; nucleic acids and proteins from group B <i>Streptococcus agalactiae</i> and group A <i>Streptococcus pyogenes</i>)</p>			
L20	ANSWER 40 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN			
ACCESSION NUMBER:	2001:713538 CAPLUS			
DOCUMENT NUMBER:	135:283990			
TITLE:	Identification of essential genes in prokaryotes and use of their antisense constructs in antibiotic screening			
INVENTOR(S):	Haselbeck, Robert; Ohlsen, Kari L.; Zyskind, Judith			

W.; Wall, Daniel; Trawick, John D.; Carr, Grant J.;
 Yamamoto, Robert T.; Xu, H. Howard
 PATENT ASSIGNEE(S): Elitra Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 511 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070955 A2		20010927	WO 2001-US9180	20010321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR			
PRIORITY APPLN. INFO.:			US 2000-PV191078	20000321
			US 2000-PV206848	20000523
			US 2000-PV207727	20000526
			US 2000-PV242578	20001023
			US 2000-PV253625	20001127
			US 2000-PV257931	20001222
			US 2001-PV269308	20010216

ED Entered STN: 28 Sep 2001

AB Genes required for proliferation of *Staphylococcus aureus*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Enterococcus faecalis*. Libraries of genomic fragments were operably cloned into vectors comprising inducible promoters in the antisense orientation, and selected for those genes which fail to grow or grow at a substantially reduced rate when the promoter is induced. The sequences of antisense nucleic acids which inhibit the proliferation of prokaryotes are disclosed. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the expressed proteins, and to use those expressed proteins as a screen to isolate candidate mols. for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than *Staphylococcus aureus*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in other organisms.

IT 297310-95-3 364143-21-5

RL: ARU (Analytical role, unclassified); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(amino acid sequence; identification of essential genes in prokaryotes and use of their antisense constructs in antibiotic screening)

L20 ANSWER 41 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:676794 CAPLUS

DOCUMENT NUMBER: 136:15927

TITLE: *Escherichia coli* polynucleotides of group B2/D+ A- and

INVENTOR(S): their medical and biotechnological applications
 Bingen, Edouard; Bonacorsi, Stephane; Clermont,
 Olivier; Nassif, Xavier; Tinsley, Colin
 PATENT ASSIGNEE(S): Institut National de la Sante et de la Recherche
 Medicale (I.N.S.E.R.M.), Fr.
 SOURCE: PCT Int. Appl., 646 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066572	A2	20010913	WO 2001-EP3445	20010312
WO 2001066572	A3	20030501		
WO 2001066572	C2	20020815		
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
FR 2806096	A1	20010914	FR 2000-3145	20000310
CA 2402602	AA	20010913	CA 2001-2402602	20010312
EP 1328641	A2	20030723	EP 2001-917119	20010312
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2004512817	T2	20040430	JP 2001-565736	20010312
US 2003148324	A1	20030807	US 2002-238075	20020910
PRIORITY APPLN. INFO.:			FR 2000-3145	A 20000310
			FR 2001-1449	A 20010202
			WO 2001-EP3445	W 20010312

ED Entered STN: 14 Sep 2001

AB The present invention relates to products which are of nature B2+ A-, isolated from E. coli, and to their biol. applications, in particular their medical (therapeutic, vaccine and diagnostic) and biotechnol. applications. Subtractive hybridization of group B2 E. coli (strain C5 associated with neonatal meningitis) from that of E. coli strains of group A (nonpathogenic strains ECOR4 and ECOR15) yielded libraries of DNA fragments of C5+A- clones with inserts ranging from 100 to 500 bp long. Sequencing of 494 clones yielded 259 clones which are different from each other and which exhibit no significant homol. with E. coli K12; 153 of these clones are novel as products and the other fragments exhibit homol. with known products. The polynucleotides are useful for medical applications in neonatal meningitis and extra-intestinal infections by E. coli, as well as in animal models for studying E. coli virulence. A PCR method was also developed for rapidly determining the phylogenic group (A, B1, B2 and D) of E. coli strains with >99% precision, based on the chuA and yjaA genes and a novel DNA fragment named Tspe4.C2. Subtractive hybridization DNA fragment libraries are also provided for strain CFT073 subtracted from strain K12, as well as for strain RS218+/K12-.

IT 361399-37-3 374824-59-6

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(amino acid sequence; Escherichia coli polynucleotides of group B2/D+ A- and their medical and biotechnol. applications)

L20 ANSWER 42 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:168177 CAPLUS

DOCUMENT NUMBER: 134:217175

TITLE: Sugar alcohol phosphatases or sugar phosphatases as

novel targets for antiparasitic agents and use of the inhibitors in biocides and pharmaceuticals

INVENTOR(S): Thevelein, Johan; Van Dijck, Patrick

PATENT ASSIGNEE(S): K.U. Leuven Research & Development, Belg.

SOURCE: PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016357	A2	20010308	WO 2000-EP8410	20000829
WO 2001016357	A3	20011129		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1081232	A1	20010307	EP 1999-202805	19990830
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1206568	A2	20020522	EP 2000-964054	20000829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRIORITY APPLN. INFO.:			EP 1999-202805	A 19990830
			EP 2000-870145	A 20000627
			WO 2000-EP8410	W 20000829

ED Entered STN: 09 Mar 2001

AB The use of an enzyme found in fungi, bacteria, insects, nematodes, worms, mites, protozoa etc. as a target in a screening assay is described by means of which agents capable of inhibiting the function of that enzyme may be identified. The screening assay may include complete cell or purified-enzyme assays. In particular, the present invention relates to a screening assay for inhibitors or suppressors of sugar alc. phosphatases or sugar phosphatases, and more in particular inhibitors or suppressors of trehalose-6-phosphate phosphatase, as well as prepns., in particular, pharmaceutical prepns., which include inhibitors or suppressors obtained from the screening assay. Inhibitors are described as well as applications in biocides and antifungal pharmaceuticals.

IT 329336-71-2

RL: PRP (Properties)

(unclaimed sequence; sugar alc. phosphatases or sugar phosphatases as novel targets for antiparasitic agents and use of the inhibitors in biocides and pharmaceuticals)

L20 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:384488 CAPLUS

DOCUMENT NUMBER: 133:39115

TITLE: Development of novel antimicrobial agents based on bacteriophage genomics

INVENTOR(S): Pelletier, Jerry; Gros, Phillippe; Dubow, Michael

PATENT ASSIGNEE(S): Phagotech, Inc., Can.

SOURCE: PCT Int. Appl., 456 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 8
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000032825	A2	20000608	WO 1999-IB2040	19991203
WO 2000032825	A3	20010118		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6982153	B1	20060103	US 1999-407804	19990928
US 6783930	B1	20040831	US 1999-454252	19991202
CA 2353563	AA	20000608	CA 1999-2353563	19991203
EP 1135535	A2	20010926	EP 1999-958449	19991203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002531107	T2	20020924	JP 2000-585456	19991203
AU 774841	B2	20040708	AU 2000-15815	19991203
PRIORITY APPLN. INFO.:				
			US 1998-110992P	P 19981203
			US 1999-326144	A 19990603
			US 1999-407804	A 19990928
			US 1999-157218P	P 19990930
			US 1999-168777P	P 19991201
			US 1999-454252	A 19991202
			WO 1999-IB2040	W 19991203

ED Entered STN: 09 Jun 2000

AB A method for identifying suitable targets for antibacterial agents based on identifying targets of bacteriophage-encoded proteins is described. Also described are compns. useful in the identification methods and in inhibiting bacterial growth, and methods for preparing and using such compns. These methods and compns. are based on the nucleotide sequences of the genomes of Staphylococcus aureus bacteriophages 77, 3A, 96, and 44AHJD; Enterococcus bacteriophage 182; and Streptococcus pneumoniae bacteriophage Dp-1. Individual open reading frames (ORFs) and the deduced amino acids sequences of their protein products are also provided.

IT 274939-74-1

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
 (amino acid sequence; development of novel antimicrobial agents based on bacteriophage genomics)

=> sel hit rn 120 1-43
 SELECT IS APPROXIMATELY 95% COMPLETE
 E1 THROUGH E73 ASSIGNED

=> => d his 121

*Not Re-3m, this is selected out of
 Re-3m & inserted into
 Re-3m, to get hit sequences.*

(FILE 'REGISTRY' ENTERED AT 15:02:56 ON 21 SEP 2006)

FILE 'CAPLUS' ENTERED AT 15:02:56 ON 21 SEP 2006

FILE 'REGISTRY' ENTERED AT 15:03:57 ON 21 SEP 2006

FILE 'CAPLUS' ENTERED AT 15:03:57 ON 21 SEP 2006
SEL HIT RN L20 1-43

FILE 'REGISTRY' ENTERED AT 15:05:31 ON 21 SEP 2006

L21 73 S E1-E73 AND L2

=> d cn sql kwic nte l21 1-73; fil hom

L21 ANSWER 1 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein EbhA (Staphylococcus aureus) (9CI) (CA INDEX NAME)
OTHER NAMES:

CN 12: PN: WO2006032500 SEQID: 12 claimed protein

SQL 3890 SQL = *sequence length*

RN 881860-68-0 REGISTRY *Use Registry # to match sequence to reference*

SEQ 1101 SEYQTANAAG TATVTIAKGQ SFNIGDIKQY FTLSNGQAIP NGTFTNITSD

=====

HITS AT: 1111-1116

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

L21 ANSWER 2 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein EbhA (Staphylococcus aureus) (9CI) (CA INDEX NAME)
OTHER NAMES:

CN 12: PN: WO2006032475 SEQID: 12 claimed protein

SQL 3492

RN 881704-53-6 REGISTRY

SEQ 1001 DGSSTTLDAT NVMTYEPVVK SEYQTANAAG TATVTIAKGQ SFNIGDIKQY

=====

HITS AT: 1031-1036

L21 ANSWER 3 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein HectH9 (human) (9CI) (CA INDEX NAME)
OTHER NAMES:

CN 20: PN: WO2006018654 FIGURE: 8 claimed sequence

SQL 4374

RN 877096-63-4 REGISTRY

SEQ 3501 TPTPTAPTPT VTSAPALVAA TAISTIVVAA STTVTPTPTA TTTVSISPTT

== ==

HITS AT: 3539-3544

L21 ANSWER 4 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Antigenic protein EAEC45 (enterotoxigenic Escherichia coli) (9CI) (CA INDEX NAME)
OTHER NAMES:

CN 615: PN: WO2005103073 SEQID: 776 claimed protein

SQL 1153

RN 868801-62-1 REGISTRY

SEQ 1001 IFTATTTVAA YTLKAQVSQT NGQVSTKTAE SKFVADDKNA ELTASSDVQS

=====

HITS AT: 1003-1008

L21 ANSWER 5 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Antigenic protein ECs0336 (Escherichia coli) (9CI) (CA INDEX NAME)
OTHER NAMES:

CN 157: PN: WO2005103073 SEQID: 317 claimed protein
SQL 1407
RN 868799-15-9 REGISTRY

SEQ 1251 GQAIFTATTT VAAKYTLTAK VSQADGQEST KTAESKFVAD DTNAVLTAASS

=====

HITS AT: 1256-1261

L21 ANSWER 6 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Immunoglobulin, anti-(human CD20 (antigen)) (Mus musculus hybridoma 2H7
single-chain) fusion protein with glycoprotein CD40-L (antigen CD40
ligand) (human fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 7: PN: WO2005017148 SEQID: 7B claimed protein
SQL 386
RN 845951-60-2 REGISTRY

SEQ 251 WYFDVWGTGT TTVVSDPENS FEMQKGDQNP QIAAHVISEA SSKTTSVLQW

=== ===

HITS AT: 258-263

NTE

type	location			description
uncommon	Aaa-383	-	-	
uncommon	Aaa-384	-	-	

L21 ANSWER 7 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Staphylococcus aureus strain Mu50 proliferation-required gene
SAV2221) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 736: PN: US20050026189 SEQID: 742 claimed protein
SQL 286
RN 834940-01-1 REGISTRY

SEQ 51 QNINALLKPT TGTVTDDIT ITHKTKDKYI RPVRKRIGMV FQFPESQLFE

=====

HITS AT: 61-66

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L21 ANSWER 8 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Enterococcus faecalis clone WO2004106367-SEQID-473 immunogenic)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 476: PN: WO2004106367 SEQID: 473 claimed protein
SQL 60
RN 805337-13-7 REGISTRY

SEQ 1 SCAFCHVSFV GKYFRSPATG TTTIPAFVI RKFNALTRSA RASGEEKAIS

== ==

HITS AT: 19-24

L21 ANSWER 9 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Enterococcus faecalis clone WO2004106367-SEQ-ID-172 immunogenic)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 173: PN: WO2004106367 SEQID: 172 claimed protein
SQL 871

RN 805334-30-9 REGISTRY

SEQ 651 TQNTAGVTFT EKQHNVAKEI SYTVNVPANT QAYLSLFPTD FAQLESSTAT
701 VTVNGSSQQS QIGITGQYYN LGYYPKDTTV NFKVSFYGTK AVSFVQPQVV
===

HITS AT: 698-703

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

L21 ANSWER 10 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Hyperimmune serum reactive antigen (Streptococcus agalactiae clone gbs
1356) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 314: PN: WO2004099242 SEQID: 311 claimed protein

SQL 1634

RN 795869-09-9 REGISTRY

SEQ 51 QADEVGRTVA TSVQTETNPA TNLKENQPSP IAEQKDSLAA TGQSTGTVTV
=====

HITS AT: 95-100

L21 ANSWER 11 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Staphylococcus aureus clone WO2002086097-SEQID-12611) (9CI) (CA
INDEX NAME)

OTHER NAMES:

CN 2422: PN: WO02086097 SEQID: 12610 claimed protein

SQL 5795

RN 775483-52-8 REGISTRY

SEQ 1101 SEYQTANAAG TATVTIAKGQ SFNIGDIKQY FTLSNGQAIP SGTFTNITSD
=====

HITS AT: 1111-1116

L21 ANSWER 12 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Staphylococcus aureus clone WO2002086097-SEQID-12307) (9CI) (CA
INDEX NAME)

OTHER NAMES:

CN 2182: PN: WO02086097 SEQID: 12306 claimed protein

SQL 593

RN 775481-12-4 REGISTRY

SEQ 151 YQNIISKVFT LPQDFTIIAL TATATVEVQQ DIREKLNIAQ TDQIKTSTKR
=====

HITS AT: 171-176

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

L21 ANSWER 13 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Staphylococcus aureus clone WO2002086097-SEQID-12235) (9CI) (CA
INDEX NAME)

OTHER NAMES:

CN 2127: PN: WO02086097 SEQID: 12234 claimed protein

SQL 286

RN 775480-57-4 REGISTRY

SEQ 51 QNINALLKPT TGTVTVDIT ITHKTKDKYI RPVRKRIGMV FQFPESQLFE
=====

HITS AT: 61-66

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L21 ANSWER 14 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Staphylococcus aureus clone WO2002086097-SEQID-5550) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4571: PN: WO02086097 SEQID: 5550 claimed protein
SQL 273
RN 775415-96-8 REGISTRY

SEQ 1 TPYQHQAIDH VNTEFEQGY YAIVGQTGSG KSTLIQNINA LLKPTTGTVT
=====

51 VDDITITHKT KDKYIRPVRK RIGMVVFQFPE SQLFEDTVER EMIFGPKNFK

=

HITS AT: 46-51

RELATED SEQUENCES AVAILABLE WITH SEQLINK

NTE

type	location	description
uncommon	Aaa-272	-

L21 ANSWER 15 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Pseudomonas aeruginosa clone WO2002086097-SEQID-5125) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4146: PN: WO02086097 SEQID: 5125 claimed protein
SQL 725
RN 775411-62-6 REGISTRY

SEQ 551 DHRPMRLRIQ KEAAGKRFLN LFCYTATATV HAARGGARST TSVDLSKTYL
=====

HITS AT: 575-580

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L21 ANSWER 16 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Transcription factor NF- κ B pathway-associated protein (human clone 127) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 118: PN: US20040086896 SEQID: 118 claimed protein
SQL 510
RN 685914-31-2 REGISTRY

SEQ 101 AWVGLASGV GLLASLGCGL LYATVTITC QYFDDRRGLA LGLISTGSSV
=====

HITS AT: 123-128

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L21 ANSWER 17 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (human clone WO2004035732-SEQID-1941 fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1939: PN: WO2004035732 SEQID: 1941 claimed protein
SQL 561
RN 681877-58-7 REGISTRY

CN 2891: PN: US6610836 SEQID: 13591 claimed protein
SQL 121
RN 581930-51-0 REGISTRY

SEQ 1 LMSSVANWSY TATATIWRRI RDADGSDDTG GGQPYGWEAP IAILCDYQGG
=====

HITS AT: 11-16

L21 ANSWER 23 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Klebsiella pneumoniae strain ATCC202080 clone
US6610836-SEQID-13014 open reading frame-encoded) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2314: PN: US6610836 SEQID: 13014 claimed protein
SQL 1049
RN 581924-74-5 REGISTRY

SEQ 51 PGADAETVQN TVTQVIEQNM NGIDHLMYMS SNGDSTGTAT ITLTFESGTD
=====

HITS AT: 86-91

L21 ANSWER 24 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Klebsiella pneumoniae strain ATCC202080 clone
US6610836-SEQID-8258 open reading frame-encoded) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1087: PN: US6610836 SEQID: 8258 claimed protein
SQL 355
RN 581877-64-7 REGISTRY

SEQ 1 RNLRLRDMTF FRPALLGACV LFSGWVSATT PATPTATATV LDGKTMGTFW
=====

HITS AT: 35-40

L21 ANSWER 25 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Escherichia coli strain RS218 clone US030148324-SEQID-1407 open
reading frame) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1403: PN: US20030148324 SEQID: 1407 claimed protein
SQL 479
RN 573742-31-1 REGISTRY

SEQ 201 DKSQIREWFG ENTLTQMNG AITTLHGVD LALVTFDALL DTATATVACP
=====

HITS AT: 242-247

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

L21 ANSWER 26 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Escherichia coli strain CFT073 clone US030148324-SEQID-804 open
reading frame) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 802: PN: US20030148324 SEQID: 804 claimed protein
SQL 359
RN 573735-22-5 REGISTRY

SEQ 301 PAARLGKQRV QISRTGILRA SFAAPATGTV TVSLGRYQGL IPAFSIRNRE
=====

HITS AT: 327-332

L21 ANSWER 27 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (human gene 41590 protein kinase sequence homolog fragment) (9CI)

SEQ 101 VSKEILLEM F KYNKFKCRIL NEKVNTATTT VYRCGPLIDL CKGPHVRHTG

=====

HITS AT: 126-131

L21 ANSWER 18 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (human clone WO2004035732-SEQID-1940 fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1938: PN: WO2004035732 SEQID: 1940 claimed protein

SQL 351

RN 681877-57-6 REGISTRY

SEQ 101 VSKEILLEM F KYNKFKCRIL NEKVNTATTT VYRCGPLIDL CKGPHVRHTG

=====

HITS AT: 126-131

L21 ANSWER 19 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Secretory protein (Bacillus licheniformis clone WO2003093453-SEQID-24) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 16: PN: WO03093453 SEQID: 24 claimed protein

SQL 448

RN 622412-43-5 REGISTRY

SEQ 351 PSKTNPYGL GWRLNGNTDM EWMFGKHASS KAYHTGWTG TVTIIDPVYQ

== =====

HITS AT: 389-394

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L21 ANSWER 20 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (Enterococcus faecalis strain 14336 open reading frame 6257628_f1_1 fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4997: PN: US6617156 SEQID: 4997 claimed protein

SQL 797

RN 585657-03-0 REGISTRY

SEQ 601 NVPANTQAYL SLFPTDFAQL ESSTATVTVN GSSQSQIGI TGQYYNLGY

=====

HITS AT: 624-629

L21 ANSWER 21 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (Enterococcus faecalis strain 14336 open reading frame 4179211_c3_7 fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4420: PN: US6617156 SEQID: 4420 claimed protein

SQL 905

RN 585651-26-9 REGISTRY

SEQ 1 QASIVVTVFI ENTAQKGSIN IVQDKESQ RLTGAEFQWK DTVTGKTGT

=====

51 TVGTDGTVTI PNLAVNRTYE LTETKAPTGY VLDKTVHKVT LTTAQANKVV

==

HITS AT: 47-52

L21 ANSWER 22 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (Klebsiella pneumoniae strain ATCC202080 clone US6610836-SEQID-13591 open reading frame-encoded) (9CI) (CA INDEX NAME)

OTHER NAMES:

(CA INDEX NAME)

OTHER NAMES:

CN 42: PN: W003057841 FIGURE: 2 claimed protein
SQL 878
RN 564490-86-4 REGISTRY

SEQ 1 DDPVEAVLGD VTTATVTILD QEAAGSLILP APPIVVTLAD YDHVEEVTKE

=====

HITS AT: 13-18

L21 ANSWER 28 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (Enterococcus faecium clone US6583275-SEQID-7258 fragment) (9CI)
(CA INDEX NAME)

OTHER NAMES:

CN 3604: PN: US6583275 SEQID: 7258 claimed protein
SQL 616
RN 543797-67-7 REGISTRY

SEQ 151 RWNVRMIAID EAHCISQWGH DFRPSYLQMA NQLDQLPNRP VIVALTATAT

=====

201 VQVAADIKRL LKIPENNNHIQ TGFERENLRF QVIKDQKKEQ YLIEYLKINK

=

HITS AT: 196-201

L21 ANSWER 29 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Immunoglobulin, anti-(human antigen CD83) (rabbit clone M83 020B08 light
chain) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 58: PN: W003045318 SEQID: 58 claimed protein
SQL 236
RN 540550-65-0 REGISTRY

SEQ 151 ATGTVTVIVCV ANKYFPDVTV TWEVDGTTQT TGIENSKTPQ NSADCTYNLS

=====

HITS AT: 152-157

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L21 ANSWER 30 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Immunoglobulin, anti-(human antigen CD83) (rabbit clone 14C12 light chain)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 18: PN: W003045318 SEQID: 19 claimed protein
SQL 238
RN 540550-50-3 REGISTRY

SEQ 151 EVATGTVTIV CVANKYFPDV TVTWEVDGTT QTTGIENSKT PQNSADCTYN

=====

HITS AT: 154-159

RELATED SEQUENCES AVAILABLE WITH SEQLINK

NTE

type	location	description
uncommon	Aaa-3	-

L21 ANSWER 31 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Immunoglobulin, anti-(human antigen CD83) (rabbit clone M83 006G05 light

chain) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 62: PN: WO03045318 SEQID: 62 claimed protein

SQL 236

RN 540550-46-7 REGISTRY

SEQ 151 ATGTVTIVCV ANKYFPDVTV TWEVDGTTQT TGIENSKTPQ NSADCTYNLS

=====

HITS AT: 152-157

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L21 ANSWER 32 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Immunoglobulin, anti-(human antigen CD83) (rabbit clone 11G05 light chain)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 14: PN: WO03045318 SEQID: 15 claimed protein

SQL 238

RN 540550-40-1 REGISTRY

SEQ 151 EVATGTVTIV CVANKYFPDV TVTWEVDGTT QTTGIENSKT PQNSADCTYN

=====

HITS AT: 154-159

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L21 ANSWER 33 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Immunoglobulin, anti-(human antigen CD83) (rabbit clone 20D04 light chain)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 10: PN: WO03045318 SEQID: 11 claimed protein

SQL 239

RN 540550-36-5 REGISTRY

SEQ 151 DEVATGTVTI VCVANKYFPD VTVTWEVDGT TQTTGIENSK TPQNSADCTY

=====

HITS AT: 155-160

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L21 ANSWER 34 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (Acinetobacter baumannii strain 15839 clone US6562958-SEQID-5540
open reading frame-encoded) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1414: PN: US6562958 SEQID: 5540 claimed protein

SQL 354

RN 518382-28-0 REGISTRY

SEQ 201 VSPWTATTTI GAIATGSTAN VMQYGINQKL SNQMITQKDV IINAVSGAIG

=====

HITS AT: 205-210

L21 ANSWER 35 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (Pseudomonas aeruginosa strain 19804 clone US6551795-SEQID-31632
fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2632: PN: US6551795 SEQID: 31632 claimed protein

SQL 100

RN 509226-42-0 REGISTRY

SEQ 51 SSLTTYQVAT GTATVMAFTL MFGIQSLTGS ARPSLLVAKI PGRFTPVCRV

= =====

HITS AT: 60-65

L21 ANSWER 36 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (Pseudomonas aeruginosa strain 19804 clone US6551795-SEQID-30227
fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1227: PN: US6551795 SEQID: 30227 claimed protein

SQL 2736

RN 509212-38-8 REGISTRY

SEQ 2351 PFTIDTIPPA TPVLSLVGNI LTISAEPGTE LTVTVDVGGV TATATVTADN

=====

HITS AT: 2391-2396

L21 ANSWER 37 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (Pseudomonas aeruginosa strain 19804 clone US6551795-SEQID-28597
fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3597: PN: US6551795 SEQID: 28597 claimed protein

SQL 287

RN 509196-08-1 REGISTRY

SEQ 251 RPPDRRHRHR QRRDPAPLPA ARRTATATVA QPAAEPG

=====

HITS AT: 274-279

L21 ANSWER 38 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (Pseudomonas aeruginosa strain 19804 clone US6551795-SEQID-25893
fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 893: PN: US6551795 SEQID: 25893 claimed protein

SQL 156

RN 509169-05-5 REGISTRY

SEQ 1 STRRASAASA TGTPARASPW KTATSACRCP ARKTTASTAT TTVTPCATAA

=== ===

HITS AT: 38-43

L21 ANSWER 39 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (Pseudomonas aeruginosa strain 19804 clone US6551795-SEQID-18605
fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2034: PN: US6551795 SEQID: 18605 claimed protein

SQL 778

RN 508404-55-5 REGISTRY

SEQ 601 LFLDHRPMRL RIQKEAAGKR FLNLF CYTAT ATVHAARGGA RSTTSVDLSK

=== ===

HITS AT: 628-633

L21 ANSWER 40 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (Streptococcus agalactiae strain ATCC12403 clone
FR2824074-SEQID-1437) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 137: PN: FR2824074 SEQID: 1437 claimed protein

SQL 346

RN 479012-16-3 REGISTRY

SEQ 101 AEGRPSNNEE ALALTMPSGE TLEQAFVTAT ATIGEKISFR RFALVEKTDE
=====
HITS AT: 128-133

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

L21 ANSWER 41 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Streptococcus agalactiae strain ATCC12403 clone
FR2824074-SEQID-1227) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 430: PN: FR2824074 SEQID: 1227 claimed protein
SQL 1596
RN 478896-49-0 REGISTRY

SEQ 51 AATGQSTGTV TVTVPHDKVT QAVDKAKTEG IKAVQDKPMD LGNTVSA AET
=====
HITS AT: 57-62

L21 ANSWER 42 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Staphylococcus haemolyticus clone SHA101919 essential) (9CI) (CA
INDEX NAME)
OTHER NAMES:
CN 1834: PN: WO02077183 SEQID: 71834 claimed protein
SQL 423
RN 477416-07-2 REGISTRY

SEQ 351 ADMETGTATI KPSSLNGAEV YASDLRAGAC LIIAGLLAEG VTTIYNVRHI
=====
HITS AT: 355-360

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

L21 ANSWER 43 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Staphylococcus aureus clone SAU800721 essential) (9CI) (CA INDEX
NAME)
OTHER NAMES:
CN 264: PN: WO02077183 SEQID: 70264 claimed protein
SQL 593
RN 477395-07-6 REGISTRY

SEQ 151 YQNVISKVFT LPQDFTIIAL TATATVEVQQ DIREKLNIAQ TDQIKTSTKR
=====
HITS AT: 171-176

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

L21 ANSWER 44 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Staphylococcus aureus clone SAU402924 essential) (9CI) (CA INDEX
NAME)
OTHER NAMES:
CN 192: PN: WO02077183 SEQID: 70192 claimed protein
SQL 866
RN 477394-36-8 REGISTRY

SEQ 151 KPEYQTVNAA KTATVTIAKG QSFSIGDIKQ YFTLSNGQPI PSGTFTNITS
=====
HITS AT: 162-167

L21 ANSWER 45 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Pseudomonas aeruginosa clone PAE201873 essential) (9CI) (CA

CN 3692: PN: WO02077183 SEQID: 53692 claimed protein
SQL 366
RN 477012-17-2 REGISTRY

SEQ 251 PAADGKPRYV TNIDAATGTV TVGSRENLV IALTADRLKY LHPAMTGSFE

==== ==

HITS AT: 267-272

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L21 ANSWER 55 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Clostridium acetobutylicum clone CAC100049 essential) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1488: PN: WO02077183 SEQID: 51488 claimed protein
SQL 386
RN 476990-25-7 REGISTRY

SEQ 351 TTTVITPTGT TTVITPSGTT TTGTTPTDIG AIYVDD

=== ===

HITS AT: 358-363

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L21 ANSWER 56 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Bordetella pertussis clone BPT100584 essential) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 898: PN: WO02077183 SEQID: 50898 claimed protein
SQL 479
RN 476984-42-6 REGISTRY

SEQ 151 AQRGAWASTL QACERVGHQP FTAVAPDELA RRTGSPVHLE GIFDTATATV

=====

HITS AT: 195-200

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L21 ANSWER 57 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Bacteroides fragilis clone BFR12227 essential) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2948: PN: WO02077183 SEQID: 48948 claimed protein
SQL 734
RN 476964-99-5 REGISTRY

SEQ 601 VSNEPLYPPFG YGLSYTTFAY SDIHLSSSTEM SADGELTATV TVTNTGSRDG

==== ==

HITS AT: 637-642

L21 ANSWER 58 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Staphylococcus aureus clone SAU802221 essential) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2395: PN: WO02077183 SEQID: 44395 claimed protein
SQL 286
RN 476919-75-2 REGISTRY

SEQ 51 QNINALLKPT TGTVTVDIT ITHKTKDKYI RPVRKRIGMV FQFPESQLFE

=====

HITS AT: 61-66

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

L21 ANSWER 59 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Staphylococcus aureus strain NCTC8325 clone WO02094868-SEQID-5190) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5157: PN: WO02094868 SEQID: 5190 claimed protein
SQL 286
RN 476578-60-6 REGISTRY

SEQ 51 QNINALLKPT TGTVTVDDIT ITHKTKDKYI RPVRKRIGMV FQFPESQLFE
=====

HITS AT: 61-66

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

L21 ANSWER 60 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Staphylococcus aureus strain NCTC8325 clone WO02094868-SEQID-4496) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4476: PN: WO02094868 SEQID: 4496 claimed protein
SQL 9535
RN 476571-96-7 REGISTRY

SEQ 1101 PEYQTVNAAK TATVTIAKGQ SFSIGDIKQY FTLSNGQPIP SGTFTNITS
=====

HITS AT: 1111-1116

L21 ANSWER 61 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Staphylococcus aureus strain NCTC8325 clone WO02094868-SEQID-3088) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3075: PN: WO02094868 SEQID: 3088 claimed protein
SQL 593
RN 476558-05-1 REGISTRY

SEQ 151 YQNVISKVFT LPQDFTIIAL TATATVEVQQ DIREKLNIAQ TDQIKTSTKR
=====

HITS AT: 171-176

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

L21 ANSWER 62 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN hemagglutinin/hemolysin-related protein (Neisseria meningitidis) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 66: PN: WO02077648 SEQID: 66 claimed protein
SQL 2514
RN 467261-10-5 REGISTRY

SEQ 501 TPTTATGTGT ATVSISNITA PTFADGTIRT HGALDNSGSI IANGQTDVSA
=== ===

HITS AT: 508-513

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

L21 ANSWER 63 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Mycobacterium leprae gene ML0813) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 83: PN: W002074903 SEQID: 83 claimed protein

SQL 195

RN 461750-67-4 REGISTRY

SEQ 51 DNATTKAIVG APTPRPVLTT PSIPLPATPS STPPLLLLPD TATATIPKA

=====

HITS AT: 91-96

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L21 ANSWER 64 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Antigen (Staphylococcus aureus clone ORF3200) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 439: PN: W002059148 SEQID: 440 claimed protein

SQL 10498

RN 445315-39-9 REGISTRY

SEQ 1101 PEYQTVNAAK TATVTIAKGQ SFSIGDIKQY FTLSNGQPIP SGTFTNITS

=====

HITS AT: 1111-1116

NTE

type	location			description
uncommon	Aaa-9728	-	-	
uncommon	Aaa-9731	-	-	

L21 ANSWER 65 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (Bifidobacterium longum strain NCC2705 open reading frame ORF713) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 214: PN: EP1227152 SEQID: 215 claimed protein

SQL 425

RN 443410-96-6 REGISTRY

SEQ 201 MSGGQQORVA LARALAVKPR VLLLDEPLSA LDAKVRVQLR DQIRRIQLTT

=

251 GTTTFVFTHD QEEALAVADR IGVMNKGKIE QIAAPONLYQ RPATEYVATF

=====

HITS AT: 250-255

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L21 ANSWER 66 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (Bifidobacterium longum strain NCC2705 open reading frame ORF348) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 103: PN: EP1227152 SEQID: 104 claimed protein

SQL 1572

RN 443409-85-6 REGISTRY

SEQ 651 GVDSATPEVF AKTSNVKQAE GSVVIDKAAK TATVTVPARS IASIQLTGVT

=====

HITS AT: 681-686

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L21 ANSWER 67 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (Streptococcus agalactiae strain 2603V/R clone
WO0234771-SEQID-4524) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 522: PN: WO0234771 SEQID 4524 claimed protein

SQL 346

RN 440133-34-6 REGISTRY

SEQ 101 AEGRPSNNEE ALALTMPSGE TLEQAFVTAT ATIGEKISFR RFALVEKTDE

=== ===

HITS AT: 128-133

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L21 ANSWER 68 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (Escherichia coli strain RS218 clone zone84 open reading frame
orf479) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 313: PN: WO0166572 SEQID: 1407 claimed protein

SQL 479

RN 374824-59-6 REGISTRY

SEQ 201 DKSQIREWFG ENTLTQMGNG AITTLHGVAD LALVTFDALL DTATATVACP

=====

HITS AT: 242-247

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L21 ANSWER 69 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (Staphylococcus aureus clone SAU101811 proliferation-associated
fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4000: PN: WO0170955 SEQID: 5550 claimed protein

SQL 273

RN 364143-21-5 REGISTRY

SEQ 1 TPYQHQAIDH VNTFEFQGGY YAIVGQTGSG KSTLIQNINA LLKPTTGTVT

=====

51 VDDITITHKT KDKYIRPVRK RIGMVVFQFPE SQLFEDTVER EMIFGPKNFK

=

HITS AT: 46-51

RELATED SEQUENCES AVAILABLE WITH SEQLINK

NTE

type	location	description
uncommon	Aaa-272	-

L21 ANSWER 70 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN

CN Protein (Escherichia coli strain CFT073 clone zone53 open reading frame
orf359) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 77: PN: WO0166572 SEQID: 804 claimed protein

SQL 359

RN 361399-37-3 REGISTRY

SEQ 301 PAARLGKQRV QISRTGILRA SFAAPATGTV TVSLGRYQGL IPAFSIRNRE

=====

HITS AT: 327-332

L21 ANSWER 71 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN 12: PN: WO0116357 FIGURE: A-B unclaimed sequence (9CI) (CA INDEX NAME)
SQL 878
RN 329336-71-2 REGISTRY

SEQ 451 NNSPLILSEF TGTATVLKDA IMVNPWDSVG VAKTINDALM LSTKEKVSLE
=====

HITS AT: 461-466

L21 ANSWER 72 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Pseudomonas aeruginosa strain PA01 gene PA3048) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3575: PN: WO0170955 SEQID: 5125 claimed protein
CN Protein (Pseudomonas aeruginosa clone PA3048 proliferation-associated fragment)

SQL 725

RN 297310-95-3 REGISTRY

SEQ 551 DHRPMRLRIQ KEAAGKRFLN LFCYTATATV HAARGGARST TSVDSLKTYL
=====

HITS AT: 575-580

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

L21 ANSWER 73 OF 73 REGISTRY COPYRIGHT 2006 ACS on STN
CN Protein (Streptococcus phage 182 open reading frame 182ORF026) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 216: PN: WO0032825 PAGE: 324 claimed sequence

SQL 86

RN 274939-74-1 REGISTRY

SEQ 1 MEIISAVSC MRAKKLSTHE TFRIKICILD WGSIAIFYAT ATATVNMLTI
= =====

HITS AT: 40-45

FILE 'HOME' ENTERED AT 15:06:18 ON 21 SEP 2006

=>

